Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  29-Apr-2021An Open-Label, Single-Dose Study to Evaluate the 
Pharmacokinetics of Islatravir (MK-8591) in Participants with 
Moderate Hepatic Impairment
PRODUCT: MK-8591  1
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD) .
Protocol Title: An Open -Label, Single -Dose Study to Evaluate the Pharmacokinetics of 
Islatravir (MK -8591) in Participants with Moderate Hepatic Impairment
Protocol Number: 030-01
Compound Number: MK-8591
Sponsor Name:
[CONTACT_19519] & Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey, [ZIP_CODE] -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND 128,595
Approval Date: [ADDRESS_124719]: MK-8591  2
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
06CLSY
07ZLY5
PRODUCT: MK-8591  3
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124720] one 
of the laboratory parameters in inclusion criteri on#2 in Section 5.1.2 ,in order 
to optimize recruitment of hepatically impaired participants. Additionally, the 
emergency unblinding call center and photograph of ras h related text, as well as 
minor edits to the inform consent text in Section 8.4.1 are included in the 
amendment.
Original Protocol
(MK -8591- 030-00)21-JULY -[ADDRESS_124721]: MK-8591  4
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: [01]
Overall Rationale for the Amendments:
The original protocol is being amended to reduce (from 3 to 2) the minimum number of required participants with a score of [ADDRESS_124722] one of the laboratory parameters in inclusion criteri on#2 in Section 5.1.2 ,inorder to optimize recruitment of 
hepatically impaired participants. Additionally, the emergency unblinding call center and photograph of rash related text, as well as 
minor edits to the inform consent text in Section 8.4.1 are included in the amendment.
Summary of Changes Table:
Section # and Name [CONTACT_11029]  
5.1.2, In clusion Criteria for 
Hepatically Impaired 
ParticipantsReduced the minimum number of required 
participants with a score of [ADDRESS_124723] one of the laboratory parameters 
from 3 to 2 (inclusion criterion #2).Potential participants with the lab abnormality criterion 
appear quite rare in the pool of recruitable subjects. In 
order to optimize recruitment of potential subjects with 
moderate hepatic insufficiency in general and facilitate 
the understanding of the effect of hepatic insufficiency, 
this requirement is being eased. 
8.1.10 , Participant 
Blinding/UnblindingAdded emergency u nblinding call center 
related text .
“The emergency unblinding call center 
will be available so that a health care 
provider can obtain information about 
study intervention in emergency situations 
where the investigator is not available.”Text was added to c larify that an emergency u nblinding 
call center is available for the study.
06CLSY
07ZLY5
PRODUCT: MK-8591  5
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Section # and Name [CONTACT_11029]  
8.3.5, Photograph of Rash Added the new section for photographing 
skin reactions.
“Photographs of any rash are highly 
recommended to be taken immediately, 
along with any additional information that 
may assist the investigator in the 
evaluation of the skin reaction, skin 
eruption or rash occurrence, in determining 
etiology and drug relationship.”Photographs are necessary to assist the investigator to 
evaluate the skin reaction, skin eruption or rash 
occu rrence . As such, text was added regarding the 
recommended evaluation.
10.8, Appendix 8: Blood 
Volume TableRemoved “1” in prestudy column and 
added 1 to the count in the treatment 
period column for the following sample 
collection listed in the table :
Bloo d for Genetic Analysis
Blood for Plasma ISL
Blood for plasma M4To correct typographic errors. There is no sample 
collection in prestudy for the three sample types per 
Section 1.[ADDRESS_124724]: MK-8591  6
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 13
1.1 Synopsis ................................................................................................................. 13
1.2 Schema .................................................................................................................. 16
1.3 Schedule of Activities........................................................................................... 17
2 INTRODUCTION .......................................................................................................... 20
2.1 Study Rationale ....................................................................................................20
2.2 Background .......................................................................................................... 20
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 21
2.2.2 Preclinical and Clinical Studies ...................................................................21
2.2.3 Ongoing Clinical Studies ............................................................................. 22
2.3 Benefit/Risk Assessment ...................................................................................... 23
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 23
4 STUDY DESIGN ............................................................................................................ 25
4.1 Overall Design ......................................................................................................25
4.2 Scientific Rationale for Study Design ................................................................ .27
4.2.1 Rationale for Endpoints ............................................................................... 27
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 27
[IP_ADDRESS] Safety Endpoints ................................................................................ 27
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 27
[IP_ADDRESS] Pharmacodynamic Endpoints............................................................. 28
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................28
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 28
[IP_ADDRESS] Future Biomedical Research .............................................................. 28
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. [ADDRESS_124725]: MK-8591  7
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
5.2.2 Exclusion Criteria for Hepatically Impaired Participants ............................ 35
5.3 Lifestyle Considerations ...................................................................................... 37
5.3.1 Meals and Dietary Restrictions ....................................................................37
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions .............................................. 38
[IP_ADDRESS] Caffeine Restrictions .......................................................................... 38
[IP_ADDRESS] Alcohol Restrictions ........................................................................... 38
[IP_ADDRESS] Tobacco Restrictions .......................................................................... 38
5.3.3 Activity Restrictions .................................................................................... 38
5.4 Screen Failures .....................................................................................................38
5.5 Participant Replacement Strategy ......................................................................39
6 STUDY INTERVENTION ............................................................................................ 39
6.1 Study Intervention(s) Administered ...................................................................39
6.2 Preparation/Handling/Storage/Accountability ................................................. 41
6.2.1 Dose Preparation .......................................................................................... 41
6.2.2 Handling, Storage, and Accountability ........................................................ 41
6.3 Measures to Minimize Bias: Randomization and Blind ing.............................. 42
6.3.1 Intervention Assignment.............................................................................. 42
6.3.2 Stratification ................................................................................................ .42
6.3.3 Blinding ........................................................................................................42
6.4 Study Intervention Compliance .......................................................................... 42
6.5 Concomitant Therapy .......................................................................................... 42
6.5.1 Rescue Medications and Supportive Care ................................................... 44
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_124726] to Follow -up................................................................................................ .45
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 45
8.1 Administrative and General Procedures ........................................................... 46
8.1.1 Informed Consent ......................................................................................... 46
[IP_ADDRESS] General Informed Consent ................................................................ .46
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 47
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_124727]: MK-8591  8
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124728] ..................................................................... 47
8.1.4 Medical History ........................................................................................... 47
8.1.5 Prior and Concomitant Medications Review ............................................... 47
[IP_ADDRESS] Prior Medications ............................................................................... 47
[IP_ADDRESS] Concomitant Medications ..................................................................48
8.1.6 Assignment of Screening Number ............................................................... 48
8.1.7 Assignment of Treatment/Randomization Number .....................................48
8.1.8 Study Intervention Administration .............................................................. 48
[IP_ADDRESS] Timing of Dose Administration ......................................................... 48
8.1.9 Discontinuation and Withdrawal ................................................................ .48
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 49
8.1.10 Participant Blinding/Unblinding ..................................................................49
8.1.11 Domiciling ...................................................................................................49
8.1.12 Calibration of Equipment ............................................................................. 50
8.2 Efficacy/Immunogenicity Assessments .............................................................. 50
8.3 Safety Assessments ............................................................................................... 50
8.3.1 Physical Examinations ................................................................................. 50
8.3.2 Vital Signs ....................................................................................................50
[IP_ADDRESS] Resting Vital Signs ............................................................................ 51
8.3.3 Electrocardiograms ...................................................................................... 51
8.3.4 Clinical Safety Laboratory Assessments ..................................................... 52
8.3.5 Photograph of Rash ...................................................................................... 53
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 53
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 53
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Event s......55
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...55
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 55
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 55
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_124729]: MK-8591  9
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
8.8 Biomarkers ........................................................................................................... 57
8.8.1 Planned Genetic Analysis Sample Collection.............................................. 57
8.9 Future Biomedical Research Sample Collection ............................................... 57
8.10 Visit Requirements ............................................................................................... 57
8.10.1 Screening ......................................................................................................58
8.10.2 Treatment Period/Visit ................................................................................. 58
8.10.3 Discontinued Participants Continuing to be Monitored in the Study .......... 58
8.10.4 Poststudy ......................................................................................................58
8.10.5 Critica l Procedures Based on Study Objectives: Timing of Procedure .......58
8.10.6 Study Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 59
9 STATISTICAL ANALYSIS PLAN ............................................................................. 60
9.1 Statistical Analysis Plan Summary .....................................................................60
9.2 Responsibility for Analyses ................................................................................. 61
9.3 Hypotheses/Estimation ........................................................................................ 61
9.4 Analysis Endpoints ............................................................................................... 61
9.5 Analysis Populations ............................................................................................ 62
9.6 Statistical Methods ............................................................................................... 62
9.7 Interim Analyses ..................................................................................................64
9.8 Multiplicity ........................................................................................................... 64
9.9 Sample Size and Power Calculations ................................................................ .64
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS .....................................................................................................65
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_124730] f or Clinical Trials ............................................................. 65
10.1.2 Financial Disclosure ..................................................................................... 67
10.1.3 Data Protection ............................................................................................. 67
[IP_ADDRESS] Confidentiality of Data ......................................................................68
[IP_ADDRESS] Confidentiali ty of Participant Records ............................................... 68
[IP_ADDRESS] Confidentiality of IRB/IEC Information ............................................ 68
10.1.4 Publication Policy ........................................................................................ 68
10.1.5 Compliance with Study Registration and Results Posting Requirements ...69
10.1.6 Compliance with Law, Audit, and Debarment ............................................ 69
10.1.7 Data Quality Assurance ............................................................................... 70
10.1.8 Source Documents ....................................................................................... 71
10.1.9 Study and Site Closure ................................................................................. 71
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. [ADDRESS_124731]: MK-8591  10
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.3 Appendix 3: Adverse Events: Definitions and Proce dures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 74
10.3.1 Definition of AE .......................................................................................... 74
10.3.2 Definition of SAE ........................................................................................ 75
10.3.3 Additional Events Reported ......................................................................... 76
10.3.4 Recording AE and SAE ............................................................................... 76
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to t he 
Sponsor ........................................................................................................80
10.4 Appendix 4: Medical Device and Drug -device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up.............................................................................................................. 81
10.5 Appendix 5: Contraceptive Guidance ................................................................ 82
10.5.1 Definitions ....................................................................................................82
10.5.2 Contraception Requirements ........................................................................83
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 84
10.7 Appendix 7: Country -specific Requirements .................................................... 89
10.8 Appendix 8: Blood Volume Table ......................................................................90
10.9 Appendix 9: 12- Lead Electrocardiogram Abnormality Criteria .................... 91
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values .....93
10.11 Appendix 11: Abbreviations ............................................................................... [ADDRESS_124732]: MK-8591  11
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124733] OF TABLES
Table 1 Severity of Liver Disease Classification .......................................................... 26
Table 2 Study Interventions .......................................................................................... 40
Table 3 Allocation of Participants to Treatment ........................................................... 42
Table 4 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events ................................................................................. 54
Table 5 Pharmacokinetic (Blood) Collection Windows ............................................... [ADDRESS_124734]: MK-8591  12
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124735]: MK-8591  13
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: An Open -Label, Single -Dose Study to Evaluate the Pharmacokinetics of 
Islatravir (MK -8591) in Participants with Moderate Hepatic Impairment
Short Title: Islatravir (MK -8591, ISL) Hepatic Impairment Study
Acronym: Not applicable
Hypotheses, Objectives ,and Endpoints :
The study population includes male and female participants with moderate hepatic 
impairment between the ages of 18 and 75 years (inclusive) and healthy matched controls.
Primary Objectives Primary Endpoints
-To evaluate the plasma pharmacokinetics of 
ISL (e.g., AUC0 -∞, AUC0 -last, Cmax, Tmax, 
apparent terminal t ½, CL/F, and Vz/F) after a 
single oral dose of 60 mg ISL in participants 
with moderate hepatic impairment compared to 
healthy control participants.
Estimation: In participants with moderate 
hepatic impairment, plasma pharmacokinetics 
(AUC0-∞, Cmax) of ISL following a single 
60 mg ISL dose will be estimated and 
compared to those observed in healthy mean 
matched control participants.-AUC0 -∞, AUC0 -last, Cmax, Tmax, 
apparent terminal t ½, CL/F, and Vz/F of 
plasma ISL
Secondary Objectives Secondary Endpoints
-To evaluate the safety and tolerability of ISL 
in participants with moderate hepatic 
impairment.-Adverse experiences, laboratory safety 
tests, ECGs, and VSs.
-To evaluate the intracellular 
pharmacokinetics (e.g., AUC0- ∞, AUC0 -last, 
Cmax, C24, C168, C672, Tmax, and apparent 
terminal t ½) of ISL triphosphate (ISL- TP) in 
peripheral blood mononuclear cells (PBMCs) 
after a single oral dose of 60 mg ISL in 
participa nts with moderate hepatic impairment 
compared to healthy control participants.-AUC0 -∞, AUC0 -last, Cmax, C24, 
C168, C672, Tmax, and apparent term inal 
t½of ISL -TP in PBMC 
06CLSY
07ZLY5
PRODUCT: MK-8591  14
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Overall Desig n:
Study Phase Phase [ADDRESS_124736] participant’s last 
study- related tele phone call or visit.
Number of Participant s:
Approximately [ADDRESS_124737]: MK-8591  15
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Intervention Groups and Du ration :
Intervention 
Group sIntervention Group 
Name [CONTACT_111975]-8591 (ISL) 60 mg Single dose Oral Experimental
Healthy Matched 
Control Group MK-8591 (ISL) 60 mg Single dose Oral Experimental 
Total 
Number of 
Intervention 
Groups/ 
Arms2
Duration of 
ParticipationEach participant will participate in the study for approximately [ADDRESS_124738]. 
Study Governance Committees:
Steering Committee No
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
There are no governance committees in this study.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix [ADDRESS_124739]: MK-8591  16
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124740]: MK-8591  17
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
1.3 Schedule of Activities
All Participants
Intervention Notes:
Scheduled Day 1 2 2 3 4 5 6 8
Scheduled Hour Screening Check -
inPre-
dose00.25 0.5 1 2 4 6 8 12 24 36 48 72 96 120 168
Administrative /Study Procedures
Informed Consent X
Informed Consent for Future Biomedical 
ResearchX
Participant Identification Card X
Inclusion/Exclusion Criteria X X
Medical History XIncludes substance use 
(drugs, alcohol, tobacco and 
caffeine)
Prior/Concomitant Medication Review X X X------------------------------------------------------------------------------- X Refer to Section 8.1.5.
Assignment of Screening Number X Refer to Section 8.1.6.
Assignment of Treatment Number X
Domiciling X------------------------------------------------------------------------------------------------- X Refer to Section 8.1.11.
MK-8591 (ISL) Administration X
Safety Procedures
Full physical examination X XaSymptom -driven PE may be 
performed at other times, at 
the Investigator’s discretion. 
Refer to Section 8.3.1.
Height X Refer to Section 8.3.1.
Weight X Refer to Section 8.3.1.
Assessment of Liver Function using 
Child -Pugh ClassificationXTo be performed in 
participants with Hepatic 
impairment only.
Vital Signs (heart rate, blood pressure) X X X XRefer to Section 8.3.2
Respi[INVESTIGATOR_13581] X X Refer to Section 8.3.2
Body Temperature X X Refer to Section 8.3.2
12-lead ECG X X X XRefer to Section 8.3.3
Hepatitis B and C screen (per site SOP) X For healthy participants only
HIV-1, HIV -[ADDRESS_124741]: MK-8591  18
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
All Participants
Intervention Notes:
Scheduled Day 1 2 2 3 4 5 6 8
Scheduled Hour Screening Check -
inPre-
dose00.25 0.5 1 2 4 6 8 12 24 36 48 72 96 120 168
Serum/urine β -Human Chorionic 
Gonadotropin (β -hCG)X XaRequired for WOCBP.  
Serum or urine β-hCG at 
predose (per site SOP). 
Serum β-hCG required at 
Screening.  Refer to Section 
10.2
Serum Follicle Stimulating Hormone 
(FSH)XFor WONCBP. Refer to 
Section 10.2 and 10.5
GC/CT (gonorrhea + chlamydia) screen X Per site SOP
Syphilis serologic screening X Per site SOP
Trichomonas testing X If available, per site SOP
Urine or Blood Drug Screen (UDS/BDS) 
(per site SOP)/alcohol screenX XaAny additional UDS/BDS 
and alcohol screen are 
conducted per site SOP.  
Refer to Section 10.2
Hematology, urinalysis, and chemistryX Xa`` X XRefer to Section 8.3.4 and 
10.2.
AE/SAE review X-------------------------------------------------------------------------------------------------------------- X Refer to Section 8.4.
Pharmacokinetics/Biomarkers
Blood Collection for Plasma ISL XaX X X X X X X X X X X X X X XRefer to Section 8.6.1.
Blood collection for M4 metabolite XaX X X X X X X X X X X X X X X
Blood for PBMC ISL -TPbXaX X X X X
Urine collection for ISL and M4 
metabolite XcX------------------------------ X X ------- X X------X X ------X x-x x-x x --x x --xUrine intervals: Predose, [ADDRESS_124742], urine drug screen, safety labs, and blood sample for plasma ISL/M4 metabolite/PBMC ISL -TP can be conducted/collected within 24 hours prior to 
study drug administration.  Results from predose safety labs and drug/alcohol scre en must be reviewed prior to treatment allocation.
b. PBMC samples will also be analyzed for ISL diphosphate (ISL -DP) to check that sample stabilization is performed properly.  No ISL -DP concentrations or PK parameters will 
be reported.
c. A spot urine sam ple will be collected prior to study drug administration.
06CLSY
07ZLY5
PRODUCT: MK-8591  19
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124743]-trial visit/
Day 29d
Scheduled Hour 240 336 408 504 672
Administrative/ Study Procedures
Concomitant Medication Review X X X X X
Safety Procedures
Vital Signs (heart rate, blood pressure) X X X X X Refer to Section 8.3.2
AE/SAE review X X X X X
Hematology, urinalysis, and chemistry X
HIV-1, HIV -[ADDRESS_124744]: MK-8591  20
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
2 INTRODUCTION
Islatravir (MK -8591, ISL) is a novel, potent NRTTI being developed both for treatment of 
HIV-1 infection and for prevention of HIV- 1 infection in uninfected individuals at high risk.  
Currently, ISL is being evaluated in Phase 2 and Phase 3 trials at a dose of 0.75 mg QD (in 
combination with 100 mg doravirine, DOR; [STUDY_ID_REMOVED] , [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED], [STUDY_ID_REMOVED]) and in a Phase 2 trial at doses of 60 mg and 120 mg QM 
([STUDY_ID_REMOVED]).  Additional programs, with other doses and administration frequencies 
within the range of 0.75- [ADDRESS_124745] on efficacy and/or safety.
Islatravir will be administered to HIV patients with liver disease, including those co-infected 
with hepatitis C virus (HCV).  Based on the evidence to date, a major effect of hepatic 
insufficiency on islatravir PK seems unlikely, but possible.  In preclinical studi es, hepatic 
metabolic pathways do not appear to play an important role in islatravir metabolism.  The 
major metabolite of islatravir, M4 (4’ -ethynyl -2-fluoro -2’deoxyinosine), is formed by 
[CONTACT_111940] (ADA), which is a ubiquitously expressed enzyme with relatively high 
activity in liver.  Therefore, hepatic insufficiency could result in decreased ADA activity, 
potentially leading to modestly higher levels of islatravir in participants with hepatic 
insufficiency.  A greater understanding of the effect s of hepatic insufficiency on islatravir PK 
is thus considered important .
This Phase 1 study will evaluate the general tolerability and pharmacokinetics (PK) of a 
single 60 mg dose of ISL in participants with moderate hepatic insufficiency, compared to 
participants in good health.
2.2 Background
Refer to the IB/approved labeling for detailed background information on MK -8591 
(islatravir, ISL) .
HIV-1 infection remains a global health challenge, with close to 37 million people living 
with HIV/AIDS worldwide .  The use of ever -improving highly effective ARVs has greatly 
improved the natural history of HIV infection, such that HIV infection has become a chronic 
illness, provided patients remain adherent in taking ARV therapy. Globally, almost two 
million people yearly become newly infected wit h HIV, thus demonstrating a need for 
effective prevention strategies that could reduce this infection rate.  There are numerous 
barriers for many individuals in taking daily medication, including access to medica tion and 
stigma.  Several recent advances in the field, including simplification from [ADDRESS_124746]: MK-8591  22
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124747] frequently reported dru g-related AE ( ≥2% of participants in any protocol) was 
headache. 
Following oral administration, p lasma PK data indicate that ISLwas rapi[INVESTIGATOR_19627] a 
median Tmax of 0.5 hr, and an apparent terminal t½ of 47 to 64 hr after single doses. 
Intracellula r ISL-TP levels reached C maxbetween 6 to 24 hr and declined with an apparent 
terminal t½ of 79 to 214 hr. Over the entire Phase 1 clinical program, ISL plasma exposure 
and ISL- TP levels appeared to increase in an approximately dose -proportional manner 
between ISL doses of 0.2 5 and 400 mg. M4 levels, when assessed, correspond to ~30- 40% 
of ISL plasma parent levels at all dose levels tested.  Following administration of 30 mg ISL 
with a high- fat meal, PK of ISL -TP in PBMCs were largely unaffected.  Examina tions of 
DDIs between ISLand DTG/TDF, ISLand LNG/EE, ISLand DOR, and ISL and 
pantoprazole demonstrated no clinically meaningful interactions.
After ISL administ ration to treatment -naïve participants with HIV- 1 infection at doses of 
0.5mg, 1 mg, 2 mg, 10 mg ,and 30 mg , viral load reduction data show greater than 1.0 log 
drop on average at all doses tested. Pharmacokinetic data in participants infected with HIV-1 
generally were consistent with the data in healthy participants.
2.2.3 Ongoing Clinical Studi es
There are ten ongoing trials involving oral ISL. 
Protocol 015 (P015) is a multiple panel double -blind placebo- controlled trial in 76healthy 
adult Japanese males, examining PK and general safety and tolerability of ISL up to 120mg 
and 100 mg DOR.  In P015, which remains blinded, ISL (or placebo) appears to be generally 
well tolerated at all doses examined to date.  
Protocol 026 (P026) is an open -label, single -dose trial to evaluate the pharmacokinetics of 
60mg ISL in 6 participants with severe renal impairment and 6 control participants . This trial 
initiated in July 2020 and information on general tolerability is not yet available. 
Protocol MK -8591A 027 (P027) is an open -label clinical trial to evaluate the 
pharmacokinetics and relative bioavailability of three experimental presentations of the fixed 
dosed combination of [ADDRESS_124748] that is a potential partner agent.  In this trial, ISL appears generally well tolerated .
Protocol 011 (P011) is an ongoing Phase 2b trial ([STUDY_ID_REMOVED] ) in treatment -naive persons 
living with HIV -1 (PLWH), examining efficacy of daily ISL (0.25 mg, 0.75 mg, or 2.25 mg) 
initially in combination with DOR and 3TC, with 3TC discontinued based on interim 
analysis at 24 weeks, compared to participan tson DOR/3TC/TDF throughout the study 
period.  As of 3 1-Mar-2020, ISL has been administered to ~[ADDRESS_124749]: MK-8591  23
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124750] 96 weeks. The 48 -week analysis showed a numerically higher rate of drug -related 
AEs in participants who received DOR/3TC/TDF (19.4%) vs. participants on any dose of 
ISL (0%, 10%, 12.9% for 0.25 mg, 0.75mg, and 2.25 mg, respectively).  Among the 
90participants who received any dose of ISL, there was no specific drug -related AE that 
occurred in more than 5% of the participants.
Protocol 016 (P016) is a double -blind, placebo- controlled Phase 2 trial (NCT 04003103) in 
low-risk otherwise healthy individuals, examining general tolerability and PK of QM 
administration of oral ISL alone, to establish greater understa nding of potential doses for a 
QM PrEP indication.  This trial is examining doses of 60 mg and 120 mg (and placebo); the 
first participants were dosed in November 2019.  As of [ADDRESS_124751] one 
dose of ISL in this trial.
Protocols 017 -020 (P017 -P020) are Phase 3 trials in persons living with HIV -1 switching 
from current therapy (P017, P018), are heavily treatment experienced (P019), or are naïve to 
therapy ( P020).  All four of these trials initiated in early 2020; information on general 
tolerability is limited.
2.3 Benefit/Risk Asse ssment
Healthy participants in clinical studies will not receive direct benefit from treatment during 
participation as clinical studies are designed to provide information about the safety and 
effectiveness of an investigational medicine.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study may be found in the accom panying IB and informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
The study population includes male and female participants with moderate hepatic 
impairment between the ages of 18 and 75 years (inclusive) and healthy matched controls.
06CLSY
07ZLY5
PRODUCT: MK-8591  24
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Objec tives Endpoints
Primary
•To evaluate the plasma pharmacokinetics 
of ISL(e.g., AUC0-∞ , AUC0 -last, Cmax, 
Tmax, apparent terminal t½, CL/F, and 
Vz/F) after a single oral dose of 60 mg 
ISLin participants with moderate hepatic
impairment compared to healthy control 
participants .
Estimation: In participants with moderate 
hepatic impairment, pl asma 
pharmacokinetics (AUC0 -∞, Cmax) of 
ISLfollowing a single 60 mg ISL dose 
will be estimated and compared to those 
observed in healthy mean matched control 
participants .•AUC0 -∞, AUC0 -last, Cmax, Tmax, 
apparent terminal t½, CL/F, and Vz/F 
of plasma ISL
Secondary
•To evaluate the safety and tolerability of 
ISLin participants with moderate hepatic
impairment.•Adverse experiences, laboratory safety 
tests, ECGs, and VSs.
•To evaluate the intracellular 
pharmacokinetics (e.g., AUC0- ∞, AUC0 -
last, Cmax, C24, C168, C672, Tmax, and 
apparent terminal t ½) of ISL triphosphate 
(ISL-TP) in peripheral blood mononuclear 
cells (PBMCs) after a single oral dose of 
60 mg ISL in participants with moderate 
hepatic impairment compared to healthy 
control participants.•AUC0 -∞, AUC0 -last, Cmax, C24, 
C168, C672, Tmax, and apparent 
terminal t ½of ISL- TP in PBMC 
Tertiary/Exploratory
•To evaluate the plasma pharmacokinetics 
of the metabolite M4 (e.g., AUC0- ∞, 
AUC0 -last, Cmax, and Tmax,) after a 
single oral dose of 60 mg ISL in 
participants with moderate hepatic 
impairment compared to healthy control 
participants .•AUC0 -∞, AUC0 -last, Cmax, and 
Tmax, of plasma M4
06CLSY
07ZLY5
PRODUCT: MK-8591  25
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Objec tives Endpoints
•To evaluate urinary excretion of ISL and 
M4 after a single oral dose of 60 mg ISL 
in participants wi th moderate hepatic 
impairment and in healthy control 
participants.•Ae, CLr, and fe of ISL and M4 in urine
•To explore the relationship between 
genetic variation and response to the 
treatment(s) administered, and 
mechanisms of disease. Variation across 
thehuman genome may be analyzed for 
association with clinical data collected in 
this study.•Germline genetic variation and 
association to clinical data collected in 
this study
4 S TUDY DESIGN
4.1 Overall Design
This is a nonrandomized, multi- group, open -label , single -dose study of ISL in adult male and 
female participants with moderate hepatic insufficiency (N=6) and in matched healthy adult 
male and female participants (N=6) .  Once all participants with moderate hepatic
insufficiency are enrolled, t he healthy matched control participants will be enrolled. 
Individual age and weight of healthy matched control participants will be within the range ± 
10 years and ± 2.0 kg/m2of the mean age and body mass index (BMI) of participants with 
hepatic insuffici ency .  In addition, the numbers of males and females of the healthy 
participants will be generally matched to the numbers of hepatic i nsufficient participants
within ±1.
Assignment to a group will be as follows:
Impairment Stage N Child -Pugh scorea
Moderate [ADDRESS_124752] scoring (see below). Baseline Child -Pugh will be obtained twice (at least 72 hours 
apart as part of participant screening) and the mean of the two values will be used. The second Child -Pugh score may be 
calculated at the time of check -in.
bAt least 3participants witha score of at least 2 on one of the laboratory parameters (reduced serum albumin, increased 
serum bilirubin, or increased INR) will be enrolled .
On Day 1, participants will receive a single oral dose of 60 mg ISL, followed by [CONTACT_111941] 168hours postdose ( in both the healthy control group and the moderate 
hepatic impairment group).  There will be additional visits at hours 240, 336, 408, 504, [ADDRESS_124753]: MK-8591  26
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
postdose for the collection of PBMCs.  Safety will be monitored throughout the study by 
[CONTACT_81506].
As noted, t he Child -Pugh classification will be used to categorize hepatic insufficiency. The
Child -Pugh scale is utilized by [CONTACT_111942] .In the current 
study, patients with chronic, stable hepatic insufficiency with features of cirrhosis due to any 
etiology will be enrolled, and the Child -Pugh scale will be used to classify the severity of 
liver disease (Table 1). The points from each row are summed, leading to the final Child -
Pugh score.  Scores of 5- 6, 7-9, and [ADDRESS_124754] 2 on one of the laboratory parameters (reduced serum 
albumin, increased serum bil irubin, or increased INR).
Table 1 Severity of Liver Disease Classification
Points Score for Increasing Abnormality
Assessment 1 2 3
Encephalopathy†None 1 or 2 3 or 4
Ascites Absent Slight Moderate
Albumin (g/dL) >3.5 2.8 to 3.5 <2.8
International normalized ratio (INR) <1.7 1.7 to 2.3 >2.3
Bilirubin (mg/dL) —not PBC‡§
Bilirubin (mg/dL) —only for PBC‡§<2
<42 to 3
4 to 10>3
>10
†Portal -system encephalopathy is Staged 0 to 4.
‡PBC=Primary Biliary Cirrhosis.
§Select only one dependent on type of cirrhosis.
The Child- Pugh classification will be used due to its widespread use and acceptance by 
[CONTACT_17513], including the U.S. Food and Drug Administration and the European 
Committee for Medicinal Products for Hum an Use. This study design is supported by [CONTACT_111943].
Because this is a Phase [ADDRESS_124755]: MK-8591  27
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124756] of hepatic 
impairment, enrolled participants with reasonably matched demographics to mean 
demographic parameters will be enrolled.
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Efficacy Endpoints
There are no efficacy endpoints in this trial.
[IP_ADDRESS] Safety Endpoints
Multiple trials have evaluated oral ISL in human participants , including a Phase [ADDRESS_124757] safety monitoring plan consisting of adverse 
event monitoring, physical examinations, vital signs (heart rate and blood pressure), 12 -lead 
ECGs and laboratory tests (hematology, serum chemistry and urinalysis), obtained pre -and 
post-dosing, has be en deemed adequate to assess tolerability of ISL in this trial.
[IP_ADDRESS] Pharmacokinetic Endpoints
In order to evaluate the pharmacokinetics of ISLadministered to patients with moderate 
hepatic impairment , the following pharmacokinetic parameters will be evaluated: AUC0 -∞, 
AUC0 -last, Cmax, Tmax, apparent terminal t½, CL/F, and Vz/F of plasma ISL. In addition to 
assessing parent ISL levels, the following ISL -TP PK parameters will be evaluated in 
PBMCs: AUC0 -∞, AUC0 -last, Cmax, C24, C168, C672, Tmax, and apparent terminal t½ of 
ISL-TP.This intracellular evaluation will allow a more complete understanding of ISL -TP 
levels in this population. 
Assessment of these PK parameters for both ISL and ISL- TP has been consistently 
performed throughout the entire Phase 1 clinical development program.   The relationship 
between ISL and ISL- TP levels has been well characterized in healthy study participants and 
in HIV+ study participants. This assessment, however, will allow greater understanding of 
thatrelationship in hepatically impaired individuals, and can therefore determine whether 
ISL-TPlevels, which are key to defining the PK threshold for efficacy, will also be sufficient 
in this population .
In addition, the PK of M4, the major circulating metabolite of ISL, will be evaluated as an 
exploratory endpoint. As noted, there is a theoretical possibility that M4 levels could be 
06CLSY
07ZLY5
PRODUCT: MK-8591  28
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
lower in individuals with hepatic insufficiency due to lower hepatic acti vity of ADA . This 
assessment, therefore ,will allow determination of M4 plasma and urine concentrations in 
these participants .
[IP_ADDRESS] Pharmacodynamic Endpoints
No pharmacodynamic endpoints will be evaluated.
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_124758] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug absorption, distribution, metabolism, and e xcretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and IRB/IEC allow, a sample will be collected for DNA analysis 
from consenting participants.
DNA samples may be used for research related to the study intervention( s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the disease under study, related diseases, and study interventi on(s). Genetic 
research may consist of the analysis of 1 or more candidate genes , the analysis of genetic 
markers throughout the genome , or analysis of the entire genome. Analysis may be 
conducted if it is hypothesized that this may help further understand the clinical data.
The samples may be analyzed as part of a multi -study assessment of genetic factors involved 
in the response to understand study disease or related conditions.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct FBR on DNA spe cimens for which consent was pr ovided during 
this clinical study.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study) and will only be conducted on specimens from 
appropri ately consented participants. The objective of collecting/retaining specimens for 
FBR is to explore and identify biomarkers that inform the scientific understanding of 
diseases and/or their therapeutic treatments. The overarching goal is to use such information 
to develop safer, more effective drugs/vaccines, and/or to ensure that participants receive the 
correct dose of the correct drug/vaccine at the correct time. The details of FBR are presented 
inAppendix 6.
4.2.2 Rationale for the Use of Comparator/Placebo
Not applicable
06CLSY
07ZLY5
PRODUCT: MK-8591  29
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124759] oral dose being considered for pi[INVESTIGATOR_6518], as it is 
the dose being considered for Phase 3 evaluations of QM ISL for pre -exposure prophylaxis.  
As noted, the PK for both parent ISL and ISL -TP has been dose -proportional over the entire 
dose range evaluated to date (0.25 -400 mg), and thus the effects of hepatic impairm entare 
not likely to vary with dose.  A one -time dose of ISL, as being performed here, will be able 
to inform on other dose administration frequencies, as the PK parameter values obtained in 
this trial can be used to model potential effects at other doses .    
As this is a Phase 1 assessment of MK -8591 inhumans, and the PK, pharmacodynamic and 
safety profiles of the compound are still being evaluated, modifications to the dose or dosing 
regimen may be required to achieve the scientific goals of the study objectives and/or to 
ensure appropriate safety monitoring of the study participants. Details of allowed 
modifications are provided in Section 8.11.6.
4.[ADDRESS_124760] to follow -up (ie, the participant is unable to be contact[CONTACT_24992]) .
Astudy may be paused dur ing review of newly available preclinical/ clinical safety, PK , 
pharmacodynamic, efficacy, or biologic data or other items of interest, prior to a final 
decision on continuation or termination of the study. It may be necessary to keep the study 
open for gat hering/reviewing of additional supportive data to optimally complete the 
objective(s) of the study. If necessary, the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated. If the decision has been made to end the 
study following this review period, the study end will be defined as the date of the Sponsor 
decision, and this end of study date supersedes the definitions outlined above . The 
Competent Authority(ies) and IRB(s)/IEC(s) will be apprised of the maximum durat ion of 
the study beyond the last participant out and the justifica tion for keepi[INVESTIGATOR_88635].
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study early.
5 STUDY POPULATION
Male/Female participants with moderate hepatic impairmen tbetween the ages of 18 and 
75years (inclusive) and healthy matched controls will be enrolled in this study.
The individual age and weight of the healthy participants is aimed to be within the
range ±10years and ± [ADDRESS_124761]: MK-8591  30
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
be generally matched to the numbers of hepatic insufficient participants within ±1; i.e ., if 
there are 3 males and 3 females in the hepatic insufficient group, every effort will be made to 
ensure a 3:3 ratio in the healthy participants , but 2:4 or 4:2 would be acceptable as well.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
5.1.1 Inclusion Criteria for Healthy Participants
The following inclusion criteria apply to all healthy participants. A participant will be 
eligible for incl usion in the study if the participant :
Type of Participant and Disease Characteristics
1.Is in good health based on medical history, physical examination, VS measurements and 
ECGs performed prior to randomization.
Appendix 9 provides a table of the 12 -Lead Electrocardiogram Abnormality Criteria.
2.Is in good health based on laboratory safety tests obtained at the screening visit and prior 
to administration of the initial dose of study drug. Appendix 2 provides a table of 
laboratory safety tests to be performed. Appendix 10provides an algorithm for the 
assessment of out of range laboratory values.
3.Hasa BMI  ≥18.5 and ≤40 kg/m2. See Section 8.3.[ADDRESS_124762] 
whole number. BMI = weight (kg)/height (m)2.
Demographics
4.Ismale or female , from 18years to 75years of age inclusive, at the time of signing the 
informed consent.
Male Participants
No measures are needed, but contraceptive use by [CONTACT_111944].
Female Participants
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least one of the following conditions applies: 
•Is not a WOCBP
OR
06CLSY
07ZLY5
PRODUCT: MK-8591  31
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
•Is a WOCBP and using an acceptable contraceptive method, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term 
and persistent basis), as described in Appendix [ADDRESS_124763] [ 4 weeks) after study intervention. The investigator should evaluate the potential for 
contraceptive method failure (ie, noncompliance, recently initiated) in relationship to 
study intervention.
•A WOCBP must have a ne gative highly sensitive pregnancy test ([urine or serum] as 
required by [CONTACT_427]) within 24hours before study intervention.
•If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cas es, the participant must be excluded from 
participation if the serum pregnancy result is positive.
•Additional requirements for pregnancy testing during and after study intervention are 
located in Appendix 2.
•The investigator is responsible for review of me dical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.
Informed Consent
5.Provides written in formed consent/assent for the study. The participant may also provide 
consent/assent for future biomedical research. However, the participant may participate in 
the main study without participating in future biomedical research.
5.1.2 Inclusion Criteria for Hepatically Impaired Participants
The following inclusion criteria apply to all hepatically impaired participants.  A hepatically 
impaired participant will be e ligible for inclusion in the study if the participant :
Type of Participant and Disease Characteristics
1.Has a diagnosis of chronic (> 6 months), stable (no acute epi[INVESTIGATOR_111937] 2 months due to deterioration in hepatic function) hepatic insufficiency with 
features of cirrhosis due to any etiology.  
2.Has a score on the Child -Pugh scale ranging from 7 to 9 (moderate hepatic insufficiency)
at screening. At least [ADDRESS_124764] one 
of the laboratory parameters (i.e., albumin, prothrombin time, and bilirubin) at screening 
on the Child -Pugh scale.
3.With the exception of hepatic impairment, is in ge nerally good health based on medical 
history, physical examination, VS measurements and ECGs performed prior to 
randomization.  Participants with stable, chronic medical or psychiatric conditions may 
be included at the discretion of the investigator and th e Sponsor.  Appendix [ADDRESS_124765]: MK-8591  32
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
4.With the exception of hepatic impairment, is in good health based on laboratory safety 
tests obtained at the screening visit and prior to study drug administrat ion. App endix 2 
provides a table of laboratory safety tests to be performed. Appendix 10 provides an 
algorithm for the assessment of out of range laboratory values.  
5.Has a BMI ≥ 18.5 and ≤ 40 kg/m2. See Section 8.3.1 for criteria on rounding to the 
neares t whole number. BMI = weight (kg)/height (m)2.
Demographics
6.Ismale or female, from [ADDRESS_124766] one of the following conditions applies: 
•Is not a WOCBP
OR
•Is a WOCBP and using an acceptable contraceptive method,or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long 
term and persistent basis), as described in Appendix [ADDRESS_124767] dose of study intervention. The investigator 
should evaluate the potential for contraceptive method failure (ie, noncompliance, 
recently initiated) in relationship to the first dose of study intervention.
•A WOCBP must have a negative highly sensitive pregnanc y test ([urine or serum] as 
required by [CONTACT_427]) within [ADDRESS_124768] dose of study 
intervention.
•If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
•Additional requirements for pregnancy testing during and after study intervention are 
located in Appendix 2.
06CLSY
07ZLY5
PRODUCT: MK-8591  33
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
•The investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.
Informed Consent
7.Provides written in formed consent/assent for the study. The participant may also provide 
consent/assent for fu ture biomedical research. However, the participant may participate in 
the main study without participating in future biomedical research.
5.[ADDRESS_124769] be 
excluded from the study if the participant:
Medical Conditions
1.Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, 
hematological, hepatic, immunological, renal, respi[INVESTIGATOR_696], genitourinary, or major 
neurological (including stroke and chronic seizures) abnormalities or diseases. 
Participants with a remote history of uncomplicated medical events (eg, uncomplicated 
kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or 
childhood asthma) may be enrolled in the study at the discretion of the investigator.
2.Is mentally or legally incapacitated, has significant emotional problems at the time of 
prestudy (screening) visit or expected during the conduct of the study or has a history of 
clinically significant psychiatric disorder of the last 5years. Participants who have had 
situational depression may be enrolled in the study at the discretion of the investigator.
3.Has a history of cancer (malignancy).
Exceptions: (1) A dequately treated nonmelanomatous skin carcinoma or carcinoma in 
situ of the cervix or ; (2) Other malignancies which have been successfully treated with 
appropriate follow up and therefore unlikely to recur for the duration of the study, in the 
opi[INVESTIGATOR_100892] (eg, malignancies which 
have been successfully treated ≥10 years prior to the prestudy [ screening ]visit).
4.Has a history of significant multiple and/or severe allergies (eg, food, drug, late x allergy), 
or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic 
reaction) to prescription or non- prescription drugs or food.
5.Has known hypersensitivity to the active substance or any of the excipi[INVESTIGATOR_111938].
6.Is positive for hepatitis B surface antigen, hepatitis C antibodies ,HIV-[ADDRESS_124770]: MK-8591  34
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124771] 1 unit of blood (approximately 500 mL) within 
4weeks prior to the prestudy (screening) visit.
Prior/Concomitant Therapy
8.Is unable to refrain from or anticipates the use of any medication, including prescription 
and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 
half-lives) prior to study drug administration, throughout the study, until the poststudy 
visit. There may be certain medications that are permitted (see Section 6.5).
Prior/Concurrent Clinical Study Experience
9.Has participated in another investigational study within 4 weeks (or 5 half -lives, 
whichever is greater) prior to the prestudy (screening) visit. The window will be derived 
from the date of the last visit in the previous study.
Diagnostic Assessments
10.Has a QTc interval >470 for males or >4 80ms for females, has a history of risk factors 
for Torsades de Pointes (eg, heart failure/cardiomyopathy or family history of long QT 
syndrome), has uncorrected hypokalemia or hypomagnesemia, is taking concomitant 
medications that prolong the QT/QTc interv al.
Other Exclusions
11.Is not considered low risk of having HIV infection. Low risk for HIV infection is defined 
by [CONTACT_3959], within 12 months prior to the screening visit (based on self -report 
by [CONTACT_111945] [if available]):
a.No anal or vaginal intercourse with someone known to be HIV -infected, or with 
someone of unknown HIV infection status who is at increased risk of HIV infection.
b.No stimulant use (cocaine [including crack], methamphetamine, or nonphysician 
prescribed pharmac eutical grade stimulants) or inhaled nitrous oxide.
c.No illicit injection drug use of any kind.
d.No new diagnosis of a sexually transmitted infection (STI) such as gonorrhea (GC), 
chlamydia (CT), incident syphilis, or trichomoniasis (if assessment is availab le). This 
includes, but is not exclusive to, any testing performed at screening.
e.No greater than 3 different sexual partners for receptive or insertive vaginal or anal 
sex; and
f.No history of antiretroviral therapy for HIV -[ADDRESS_124772]-exposure prophylaxis. Note: individuals who have participated in studies of an 
antiretroviral, including Phase [ADDRESS_124773]: MK-8591  35
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
12.Is under the age of legal consent.
13.Is a smoker or user of electronic cigarettes and/or has used nicotine or nicotine -
containing products (eg, nicotine patch) within 3 months of screening.
14.Consumes greater than 3glass esof alcoholic beverages (1 glass is approximately 
equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] 
[29.5 mL/1 ounce]) per day. Participants who consume more than the daily limit may be 
enrolled at the discretion of the investigator .
15.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day.
16.Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) 
abuse within approximately [ADDRESS_124774] and 
negative drug screen prior to randomization.
17.Presents any concern by [CONTACT_111946].
18.Is un willing to comply with the study restrictions (see Section 5.3for a complete 
summary of study restrictions).
19.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study .
5.2.[ADDRESS_124775] be excluded from the s tudy if the participant:
Medical Conditions
1.Has ahistory of any illness that, in the opi[INVESTIGATOR_689], might confound the 
results of the study or poses an additional risk to the participant by [CONTACT_111947].
2.Is institutionalized or mentally or legally incapacitated at the time of prestudy (screening) 
visit or expected during the conduct of the study .
3.Has a history of cancer (malignancy).
Exceptions: (1) A dequately treated nonmelanomatous skin carcinoma or carcinoma in 
situ of the cervix or ; (2) Other malignancies which have been successfully treated with 
appropriate follow up and therefore unlikely to recur for the duration of the study, in the 
opi[INVESTIGATOR_100892] (eg, malignancies whi ch 
have been successfully treated ≥10 years prior to the prestudy [ screening ]visit).
06CLSY
07ZLY5
PRODUCT: MK-8591  36
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
4.Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), 
or has had an anaphylactic reaction or significant intolerability (ie, syst emic allergic 
reaction) to prescription or non- prescription drugs or food.
5.Has known hypersensitivity to the active substance or any of the excipi[INVESTIGATOR_111938].
6.Is positive for HIV-[ADDRESS_124776] 1 unit of blood (ap proximately 500 mL) within 
4weeks prior to the prestudy (screening) visit.
Prior/Concomitant Therapy
8.Is taking medications to treat chronic medical conditions andhas not been on a stable 
regimen for at least 1 month and/or is unable to withhold the use of the medication(s) 
within 4 hours prior to and 8 hours after administration of the study drug.  Exceptions 
may be granted for participants in whom a medication re gimen has been adjusted within 
the one -month window, at the discretion of the Investigator and following consultation 
with the Sponsor . See Section 5.1.2 for allowed medical conditions, and Section 6.5 for 
allowed medications. 
Prior/Concurrent Clinical St udy Experience
9.Has participated in another investigational study within 4 weeks (or 5 half -lives, 
whichever is greater) prior to the prestudy (screening) visit. The window will be derived 
from the date of the last visit in the previous study.
Diagnostic Assessments
10.Has a QTc interval >470 for males or >48 0 ms for females , has a history of risk factors 
for Torsades de Pointes (eg, heart failure/cardiomyopathy or family history of long QT 
syndrome) or is taking concomitant medications that prolon g the QT/QTc interval.
Other Exclusions
11.Is not considered low risk of having HIV infection. Low risk for HIV infection is defined 
by [CONTACT_3959], within 12 months prior to the screening visit (based on self -report 
by [CONTACT_111945] [if available]):
a.No anal or vaginal intercourse with someone known to be HIV -infected, or with 
someone of unknown HIV infection status who is at increased risk of HIV infection.
b.No stimulant use (cocaine [including crack], methamphetamine, or nonphysician
prescribed pharmaceutical grade stimulants) or inhaled nitrous oxide.
c.No illicit injection drug use of any kind.
06CLSY
07ZLY5
PRODUCT: MK-8591  37
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
d.No new diagnosis of a sexually transmitted infection (STI) such as gonorrhea (GC), 
chlamydia (CT), incident syphilis, or trichomoniasis (if as sessment is available). This 
includes, but is not exclusive to, any testing performed at screening.
e.No greater than 3 different sexual partners for receptive or insertive vaginal or anal 
sex; and
f.No history of antiretroviral therapy for HIV -[ADDRESS_124777]-exposure prophylaxis. Note: individuals who have participated in studies of an 
antiretroviral, including Phase 1 studies, may be eligible after Sponsor consultation.
12.Is under the age of legal consent.
13.Does not agree to follow t he smoking restrictions as defined by [CONTACT_47365].
14.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately equivalent to 120 mg of caffeine) ,of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day.
15.Is a r egular user of cannabis, any illicit drugs or has a history of drug abuse within 
approximately [ADDRESS_124778] an active prescription from a 
licensed health care provider.
16.Is unwilling to comply with the study restrictions (see Section 5.3for a complete 
summary of study restriction s. 
17.Presents any concern by [CONTACT_100912].
18. Is or ha s an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
5.[ADDRESS_124779] scheduled meal , 
which will occur approximately 2hours after dosing .  Thereafter, there will be no restrictions 
(other than those provided in Section 5.3.3.) regarding meals and snack(s). While in the 
CRU, participants will fast from all food and drinks except water between meals and snacks. 
Otherwise, there are no dietary restrictions other than those defined below.
06CLSY
07ZLY5
PRODUCT: MK-8591  38
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Water will be provided during study drug administration. Water will be restricted 1 hour 
prior to and 1 hour after study drug administration.
5.3.2 Caffeine, Alcohol ,and Tobacco Restrictions
[IP_ADDRESS] Caffeine Restrictions
Participants will refrain from consumption of caffeinated beverages or xanthine -containing 
products from 12 hours prior to the prestudy and poststudy visits and from 12 hours prior to 
and after study drug administration. At all other times, caffeinated beverages or xanthine -
containing products will be limited to no more than 6 units per day ( 1 unit = 120 mg of 
caffeine).
[IP_ADDRESS] Alcohol Restrictions
Participants will refrain from consumption of alcohol 24 hours prior to the prestudy and 
poststudy visits and from 24 hours prior to and after study drug administration. At all other 
times, alcohol consumption is limited to no more than approximately 3alcoholic beverages 
or equivalent (1 glass is approximately equivalent to: beer [354 mL/12 ounces], wine 
[118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] [29.5 mL/1 ounce]) per day.
[IP_ADDRESS] Tobacco Restrictions
Smoking or the use of electronic cigarettes, or the use of nicoti ne/nicotine -containing
products is not permitted for participants in the healthy control group.
Participants in the moderate hepatic impairment group will follow the smoking restrictions 
(and i f applicable, the use of electronic cigarettes or nicotine/nicotine -containing products) 
defined by [CONTACT_47365].
5.3.3 Activity Restrictions
Participants will avoid unaccustomed strenuous physical activity (ie, weight lifting, running, 
bicycling, etc.) from the prestudy (screening) visit until administration of the initial dose of 
study drug, throughout the study (including washout intervals between treatment periods) and 
until the poststudy visit.
5.[ADDRESS_124780]: MK-8591  39
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
5.5 Participant Replacement Strategy
If a participant withdraws from the study a replacement participant may be enrolled if 
deemed appropriate by [CONTACT_8981]. The replacement participant will 
generally receive the same interve ntion or intervention sequence (as appropriate) as the 
participant being replaced. The replacement participant will be assigned a unique 
treatment/randomization number. The study site should contact [CONTACT_111948]’s treatment/r andomization number.
The replacement participant may begin dosing at the subsequent dose level for that panel, 
based on investigator and Sponsor review and discussion.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study participant according to 
the study protocol .
Clinical supplie s will be packaged to support enrollment and replacem ent participants as 
required. When a replacement participant is required, the Sponsor or designee needs to be 
contact[CONTACT_111949]. Clinical supplies will be affixed with a 
clinical label in accordance with regulatory requirement s.
6.1 Study Intervention(s) Administered
The study intervention(s) to be used in this study is outlined inTable [ADDRESS_124781]: MK-8591  40
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Table 2 Study Intervention s
Arm 
NameArm 
TypeIntervention 
NameIntervention 
TypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
AdministrationRegimen/
Treatment 
Period/
Vaccination 
Regimen UseIMP/
NIMP Sourcing
Healthy 
Control 
GroupExperi -
mentalMK-8591 
(ISL)Drug Capsule 30 mg 60 mg Oral Single 
Dose on 
Day 1Experimental IMP Provided 
by [CONTACT_111950] -
ment 
GroupExperi -
mentalMK-8591 
(ISL)Drug Capsule [ADDRESS_124782] (IMP) and Non -Investigational Medicinal Product (NIMP) in this table is based on guidance issued by [CONTACT_111951] (EEA). Country differences with respect to the definition /classification of IMP/NIMP may exist. In these 
circumstances, local legislation is followed.
06CLSY
07ZLY5
PRODUCT: MK-8591  41
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
All supplies indicated in Table 2 will be provided per the "Sourcing" column depending upon 
local country operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/bat ch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc).
Refer to Section 8.1.8 for details regarding administration of the study intervention.
6.2 Preparation/Handling/Storag e/Accountability
6.2.[ADDRESS_124783] be stored 
in a secure, environmentally controlle d, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(ie,receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction proc edure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations .
06CLSY
07ZLY5
PRODUCT: MK-8591  42
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Participants will be assigned an allocation number (AN) for a single open -label treatment 
using the allocation schedule shown in Table 3 .
Table 3 Allocation of Participants to Treatment 
Hepatic Impairment Stage N Treatment
Moderate 6 MK-8591 (ISL) 60 mg
Healthy 6 MK-8591 (ISL) 60 mg
6.3.2 Stratification
No stratification based on age, sex, or other characteristics will be used in this study.
6.3.3 Blinding
This is an open -label study; therefore, the Sponsor, investigator, and participant will know 
the intervention administered.
6.4 Study Intervention Compliance
When t he individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by a second member of the study site staff.
When participants are dosed at the site, they will receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF. 
The dose of study intervention and study participant IDwill be confirmed at the time of 
dosing by a member of the study site staff other than the person administering the study 
intervention. Study site personnel will examine each participant’s mouth to ensure that the 
study intervention was ingested.
6.[ADDRESS_124784] dose of study intervention (whichever is longer), they may be included in the study if the 
investigator can rationalize that the specific use of a prior medication is not clinically 
relevant within the context of the study.
Concurrent use of any prescription or nonprescription medication, or concurrent vaccination,
during the ongoing study (ie, after intervention allocation) must first be discussed between 
the investigator and Sponsor prior to administration, unless appropriate medical care 
06CLSY
07ZLY5
PRODUCT: MK-8591  43
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
necessitates that therapy or vaccination should begin before the investigator and Sponsor can 
consult. The participant will be allowed to continue in the study if both the Sponsor and the 
investigator agree.
Ibuprofen may be used for minor ailments without prior consultation with the Sponsor.   
Paracetamol/ac etaminophen use for minor ailments requires consultation with the Sponsor.
For Participants with Moderate Hepatic Impairment: 
Participants who are taking medications to treat general medical conditions and/or conditions 
associated with hepatic disease (e.g., hypertension, non- insulin dependent diabetes mellitus, 
hypercholesterolemia, hypo- or hyperthyroidism, gout, depression) will be allowed to 
participate in the study at the discretion of the Investigator and following consultation with 
the Sponsor Clini cal Monitor. Participants must be on a stable regimen for at least [ADDRESS_124785] be discuss ed 
between the Investigator and Sponsor. 
Certain prescription medications used to treat manifestations of hepatic disease (e.g., 
lactulose, neomycin, etc.) will be allowed during the study, but the patient must be on a 
steady dose, drug, and regimen for ~ [ADDRESS_124786] 
absorption.
Examples of types of medications that would be used for chronic medical conditions that 
would be allowed include (but are not limited to) the following:
Angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, 
diuretics
Beta blockers
Metformin, thiazolidinediones, sulfonylureas, DPP -4 inhibitors, alpha -glucosidase 
inhibit ors, incretin mimetics
Statins
Levothy roxine
Colchicine, allopurinol
Selective serotonin uptake inhibitors (SSRIs), tricyclic antidepressants
Proton pump inhibitors
06CLSY
07ZLY5
PRODUCT: MK-8591  44
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Any medication (including over -the-counter) that ,by [CONTACT_111952],
might interfere with the study (e.g., cimetidine) must be discontinued at least 2 weeks 
(or5half-lives of the compound, whichever is longer) prior to the dosing of study drug.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications a re specified for use in this study.
6.6 Dose Modification (Escalation/Titration/Other)
Dose modifications are not applicable to this study.
6.6.[ADDRESS_124787] of this study.
If any of the below stoppi[INVESTIGATOR_26501], the study will be paused and no further dosing 
will occur until the Sponsor has reviewed the totality of data available. In order to continue 
the study (upon joint agreement with the Sponsor and investigator), a namendment will be 
submitted for approval.
1.An individual participant reports an SAE considered related to the study drug by [CONTACT_1275].
2.Two (2) or more participants report Severe Non -serious Adverse Events considered 
related to the study drug by [CONTACT_093].
6.7 Intervention After the End of the Study
There is no study -specified intervention following the end of the study.
6.8 Clinical Supplies Disclosure
Thisstudy is open- label; therefore, the participant, the study site personnel, the Sponsor, 
and/or designee are not blinded. Study intervention (name, strength, or potency) is included 
in the label text; random code/disclosure envelopes or lists are not provided.
[ADDRESS_124788]: MK-8591  45
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124789] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific det ails regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.9. The procedures to be performed should a participant repeatedly fail 
to return for scheduled visits and/or if the study site is unable to contact [CONTACT_111953] 7.3.
7.[ADDRESS_124790] t o Follo w-up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and analysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of study 
site personnel responsibilities will be docu mented in the Investigator Trial File Binder 
(orequivalent).
•All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
06CLSY
07ZLY5
PRODUCT: MK-8591  46
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
•Additional evaluations/testing may be deemed necessary by [CONTACT_88686]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional inform ed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the study
will not exceed 382mL(Appendix 8).
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirement s)must 
obtain documented consent from each potential participant or each participant’s legally 
acceptable representative prior to participating in a clinical study or future biomedical 
research . If there are changes to the participant’s status during the study (eg, health or age of 
majority requirements), the investigator or medically qualified designee must ensure the 
appropriate consent is in place.
[IP_ADDRESS] General Informed Consent
Consent must be documented by [CONTACT_2299]’s dated signature [INVESTIGATOR_4388] [CONTACT_2299]’s 
legally acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated 
signature [CONTACT_63564].
A copy of the signed and dated consent form should be given to the participant before 
partic ipation in the study.
The initial ICF, any subsequent revised written ICF, and any written information provided to 
the participant must receive the IRB/IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable repres entative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue participation in the study. The communication of this information will be provided 
06CLSY
07ZLY5
PRODUCT: MK-8591  47
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
and documented via a re vised consent form or addendum to the original consent form that 
captures the participant’s dated signature [INVESTIGATOR_4388] [CONTACT_2299]’s legally acceptable 
representative’s dated signature.
Specifics about a study and the study population will be added to the c onsent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically quali fied designee will explain the future biomedical r esearch 
consent to the participant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure related to future biomedical research. A copy of the 
informed consent will be given to the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the study.
8.1.[ADDRESS_124791] information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention randomization,
site personnel will add the treatment /randomization number to the participant identification 
card.
The participant identification card also contains contact [CONTACT_19430] a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history will be obtained by [CONTACT_27404].
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by [CONTACT_88688] [ADDRESS_124792]: MK-8591  48
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
[IP_ADDRESS] Concomitant Medications
The invest igator or qualified designee will record medication, if any, taken by [CONTACT_19432].
8.1.[ADDRESS_124793] not be re -used for 
different participants.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
In a situation where rerandomization of the participants is planned (eg, study extension 
periods), the rerandomization wil l be based on a new randomization schedule; however, each 
participant will retain his/her original treatment/randomization number. Only the study 
intervention regimen associated with the rerandomization period or phase may change.
8.1.8 Study Intervention Admini strati on
Administration of study intervention(s) will be monitored by [CONTACT_1755]/or study 
staff.
Participants will fast from all food and drinks, except water, for at least [ADDRESS_124794] dose.  
[IP_ADDRESS] Timing of Dose Administration
Participants will be dosed according to the SoA (Section 1.3).
8.1.[ADDRESS_124795] notify the Sponsor when a participant has been 
discontinued/withdrawn from the study. If a participant discontinues for any reason at any 
time during the course of the study, the participant may be asked to return to the clinic (or be 
contact[INVESTIGATOR_530]) for a poststudy visit as per the num ber of days described in Section 1.3to have the 
applicable procedures conducted. However, the investigator may decide to perform the 
06CLSY
07ZLY5
PRODUCT: MK-8591  49
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
poststudy procedures at the time of discontinuation or as soon as possible after 
discontinuation. If the poststudy visit occurs prior to the safety follow- up time frame as 
specified in Section 8.4.1, the investigator should perform a follow -up telephone call at the 
end of the follow -up period (Section 8.4.1) to confirm if any AEs have occurred since the 
poststudy clinic visit . Any AEs that are present at the time of discontinuation/withdrawal 
should be followed in accordance with the safety requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomed ical r esearch. Participants may 
withdraw consent at any time by [CONTACT_111954]. If medical 
records for the main study are still available, the investigator will contact [CONTACT_111955] (clinical.spec [EMAIL_2210]). Subsequently, the 
participant's consent for future biomedical r esearch will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the 
investigator to inform the participant of completion of withdrawal. Any analyses in progress 
at the time of request for withdrawal or already performed prior to the request being received 
by [CONTACT_111956] r esults. 
No new analyses would be generated after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_111957]) 
or the specimens have been completely anonymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
8.1.10 Participant Blinding/Unbl inding
This is an open -label study; there is no blinding for this study. The emergency unblinding 
call center will be available so that a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.[ADDRESS_124796]: MK-8591  50
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
8.1.12 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained are reliable and/ or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study site .
8.2 Efficacy/Immunogenicity Assessmen ts
There are no direct efficacy assessments in this study.
8.3 Safety Assessments
Details regarding specific sa fety procedures/assessments to be performed in this study are 
provided. The total amount of blood/tissue to be drawn/collected over the course of the study 
(from prestudy to poststudy visits), including approximate blood/tissue volumes 
drawn/collected by v isit and by [CONTACT_111958], can be found in Section 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination will be conducted by [CONTACT_88696] (consistent with local requirements) as per institutional standard. Height and weight 
will also be measured and recorded.
A symptom driven physical examina tion may be performed at other times at the 
Investigator’s discretion.
BMI
Body Mass Index equals a person's weight in kilograms divided by [CONTACT_55739] 
(BMI=kg/m2). Body Mass Index will be rounded to the nearest whole number according to 
the standard convention of 0.1 to 0.4 round down and 0.5 to 0.9 round up.
Body weight and height will be obtained with the participant’s shoes off and jacket or coat 
removed.
8.3.2 Vital Signs
•Body temperature, HR, RR, and BP will be assessed.
•Body temperature w ill be measured with an appropriate thermometer.
•Blood pressure and pulse measurements will be assessed with a completely automated 
device. Manual techniques will be used only if an automated device is not available.
06CLSY
07ZLY5
PRODUCT: MK-8591  51
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
•Vital signs will be measured in a semi -recumbent position after [ADDRESS_124797].
[IP_ADDRESS] Resting Vital Signs
Vital Sign Measurements (Heart Rate and Blood Pressure)
Participants should be resting in a semirecumbent position for at least [ADDRESS_124798] positioning on the participants' arm is essential to increase 
the accuracy of BP measurements.
Predose HR and BP will be in triplicate measurements, obtained at least 1 to 2 minute s apart 
within 3 hours of study drug administration. The mean of these measurements will be used as 
the baseline to calculate change from baseline for safety evaluations (and for rechecks, if 
needed). Postdose VS measurements will be single measurements.
Body Temperature
Body temperature will be measured. The same method must be used for all measurements for 
each individual participant and should be the same for all participants.
8.3.3 Electrocardiograms
•Triplicate and single 12 -lead ECG measurements will be obta ined and reviewed by [CONTACT_111959] (consistent with local requirements) as 
outlined in the SoA using an ECG machine that automatically calculates the HR and 
measures PR, QRS, QT, and QTc intervals. 
•The model of ECG machin e will remain consistent for each individual participant. 
•Special care must be taken for proper lead placement by [CONTACT_5944]. Skin should 
be clean and dry prior to lead placement. Participants may need to be shaved to ensure 
proper lead placement. Female participants may need to remove interfering garments.
•Participants should be resting in the semirecumbent position for at least 10 minutes prior 
to each ECG measurement.
•The correction formula to be used for QTc is Fridericia.
•If repeat ECGs are required, the clinical site will decide whether to leave the electrodes in 
place or mark the position of the electrodes for subsequent ECGs. To mark the position of 
the electrodes, 12- lead electrode sites will be marked on the skin of each participant with 
an ECG skin marker pen to ensure reproducible electrode placement.
•Predose ECGs will be obtained in triplicate at least 1 -2 minutes apart within 3 hours prior 
to administration of ISL. The mean of these measurements will be used as the baseline to 
calculate change from baseline for safety evaluations (and for rechecks, if needed). Post -
dose ECG measurements will be single measurements.
06CLSY
07ZLY5
PRODUCT: MK-8591  52
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
•If a participant demonstrates an increase in QTc interval ≥60 msec compared with mean 
predose baseline measurement, th e ECG will be repeated twice within 5 minutes. The 
mean value of the QTc interval from the 3 ECGs will represent the value at that time 
point. If the mean QTc interval increase from baseline for any postdose time point is 
≥60msec, the participant will con tinue to be monitored by [CONTACT_7850] 12- lead ECGs every 
15minutes for at least 1 hour or until the QTc is within 60 msec of baseline. If 
prolongation of the QTc interval ≥[ADDRESS_124799] may be appropriate and the Spo nsor should be notified.
•If the QTc interval is > [ADDRESS_124800]. The participant should be telemetry- monitored (until the QTc 
is <500 msec) or should be considered for transfer to a location where closer monitoring 
and definitive care (eg, a cardiac or intensive care unit) is available.
•If the participant has unstable hemodynamics, or has any clinically significant 
dysrhythmias noted on telemetry, the participant should be immediate ly transferred to an 
acute care setting for definitive therapy .
•If prolongation of the QTc is noted, concomitant medications that prolong QTc should be 
held until the QTc is within 60 msec of baseline and the QTc is <500 msec.
•A study cardiologist will be consulted by [CONTACT_111960].
8.3.[ADDRESS_124801] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laborator y 
reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless 
judged by [CONTACT_19448]'s c ondition.
•All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_124802] be 
conducted in accordance with the laboratory manual and the SoA .
•If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory tes ts with values considered clinically significantly abnormal during 
participation in the study or within 28days after the last dose of study intervention, every 
attempt should be made to perform repeat assessments until the values return to normal or 
basel ine or if a new baseline is established as determined by [CONTACT_093] .
06CLSY
07ZLY5
PRODUCT: MK-8591  53
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124803] the investigator in the evaluation o f the skin reaction, 
skin eruption or rash occurrence, in determining etiology and drug relationship.
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating , and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3 .
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_17071] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE a s well as other reportable safety events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
8.4.[ADDRESS_124804] be reported immediately to the Sponsor 
if the event is considered related to study intervention .
Investigators are not obligated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a
death, at any time after a participant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table [ADDRESS_124805]: MK-8591  54
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Table 4 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
Allocation
(Randomized 
participants only)Reporting Time Period:
Randomizati on/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame to 
Report Event and 
Follow -up 
Information to 
Sponsor:
NSAE Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -in 
treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -in 
treatmentReport all Report if:
-drug/vaccine related.
(Follow ongoing to 
outcome)Within 24 hours of 
learning of event
Pregnancy/
Lactation 
ExposureReport if:
-participant has been 
exposed to any 
protocol -speci fied 
intervention (eg, 
procedure, washout 
or run -in treatment 
including placebo 
run-in) Report all Previously reported –
Follow to 
completion/termination; 
report outcomeWithin 24 hours of 
learning of event
ECI (require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-potential DILI
-require regulatory 
reportingNot required Within 24 hours of 
learning of event
ECI (do not 
require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within 5 calendar 
days of learning of 
event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 calendar 
days of learning of 
event
(unless serious)
Overdose Report if:
-receiving placebo 
run-in or other run -in 
medication Report all Not required Within 24 hours of 
learning of event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=se rious adverse 
event
06CLSY
07ZLY5
PRODUCT: MK-8591  55
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in allocated partic ipants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_111961] a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about t he safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Inves tigator safety reports must be prepared for S[LOCATION_003]R saccording to local regulatory 
requirements and Sponsor policy and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific saf ety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy. 
Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
06CLSY
07ZLY5
PRODUCT: MK-8591  56
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable.
8.4.[ADDRESS_124806] for this study include: 
1.An overdose of Sponsor's product, as defined in Section 8.5.
2.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the up per limit of normal, as determined by [CONTACT_13149] -specified laboratory 
testing or unscheduled laboratory testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of ab normal hepatic tests that must trigger 
an additional evaluation for an underlying etiology. The study site guidance for 
assessment and follow up of these criteria can be found in the Investigator Study File 
Binder (or equivalent).
It may also be appropriat e to conduct additional evaluation for an underlying etiology in the 
setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and alkaline 
phosphatase that do not meet the criteria noted above. In these cases, the decision to proceed 
with additional evaluation will be made through consultation between the study investigators 
and the Sponsor Clinical Director. However, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for this study.
8.5 Treatment of Overdose
For purposes of this study, an overdose will be defined as any dose of any drug administered 
as part of the study exceeding the dose prescribed by [CONTACT_760]. It is up to the investigator 
or the reporting physician to decide whether a dose is to be considered an overdose, in 
consultation with the Sponsor.
8.6 Pharmacokinetics
The decision as to which plasma and/or urine samples collected will be assayed for 
evaluation of PK/pharmacodynamics will be collaboratively determined by [CONTACT_1034] 
(eg,samples at lower doses may not be assayed if samples at higher doses reveal 
undetect able drug concentrations). If indicated, these samples may also be assayed and/or 
pooled for assay in an exploratory manner for metabolites and/or additional 
pharmacodynamic markers.
06CLSY
07ZLY5
PRODUCT: MK-8591  57
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
8.6.1 Bloo d Collection for Plasma ISL and PBMC ISL -TP
Blood collection time poi nts for plasma ISL and M4and PBMC ISL- TP are outlined in the 
SoA (Section 1.3).  Sample collection, storage, and shipment instructions for plasma samples 
will be provided in the Study Operations Manual.
8.6.2 Urine Collection for Urinary MK-8591 and M4
Urine collection intervals for urinary ISL and M4 are outlined in the SoA (Section 1.3).  
Sample collection, storage, and shipment instructions for urine samples will be provided in 
the S tudy Operations manual .
8.7 Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
8.8 Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from a ll participants as 
specified in the SoA:
•Blood for Genetic Analysis
8.8.1 Planned Genetic Analysis Sample Collection
The planned genetic analysis sample should be drawn for planned analysis of the association 
between genetic variants in DNA and drug response. Th is sample will not be collected at the 
site if there is either a local law or regulation prohibiting collection, or if the IRB/IEC does 
not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored for future biomedical research. If the planned genetic 
analysis is not approved, but future biomedical research is approved, this sample will be 
collected for the purpose of future biomedical research.
Sample collection, storage, and shipment instruction for planned genetic analysis samples 
will be provided in the operations/laboratory manual.
8.9 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
•Leftover DNA for future research 
8.[ADDRESS_124807]: MK-8591  58
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
8.10.1 Screening
Approximately 4 weeks prior to intervention ran domization, potential participants will be 
evaluated to determine that they fulfill the entry requirements as set forth in Section 5.
Participants may be rescreened after consultation with the Sponsor. Rescreening should 
include all screening procedures listed in the SoA, including consent review. Rescreen 
procedures cannot be conducted the day prior to intervention allocation if there are Day -1 
procedures planned per protocol.
8.10.2 Treatment Period/Visit
Refer to the Schedule of Activities (Section 1.3).
8.10.3 Discontinued Participants Continuing to be Monitored in the Study
At any point if a participant discontinues from treatment but continue s to be monitored in the 
study, all of the study procedures specified in the SoA may be completed at the discretion of 
the investigator and with Sponsor agreement. The subset of study procedures completed will 
be communicated in a PCL.
8.10.4 Poststudy
Poststudy procedures will be conducted on Day 29 of the study.  
8.10.5 Critical Procedures Based on Study Objectives: Timing of Procedure
For this study, the blood sample for ISL is the critical procedure.
At any postdose time point, the blood sample for ISL needs to be c ollected as close to the 
exact time point as possible. All other procedures should be completed as close to the 
prescribed/scheduled time as possible. Study procedures can be performed prior or after the 
prescribed/scheduled time.
The order of priority can be changed during the study with joint agreement of the investigator 
and the Sponsor Clinical Director.
Any nonscheduled procedures required for urgent evaluation of safety concerns take 
precedence over all routine scheduled procedures.
The following vari ance in procedure collection times will be permitted. 
•PK Collection as outlined in Table [ADDRESS_124808]: MK-8591  59
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Table 5 Pharmacokinetic (Blood) Collection Windows
PK Collection PK Collection Window
0 -<1 hr 5 min
1 - <24 hr 15 min
24 - <48 hr 1 hr
48 -≤120 hr 2 hr
120 – 168 hr 6 hr
˃168 hr 24 hr
•Predose standard safety evaluations: vital signs and ECG up to 3 hrs; laboratory safety 
tests and physical exam up to 24 hrs
•Postdose standard safety evaluations: vital signs, ECG, laboratory safety tests, and 
physical exam
-<24 hr postdose may be obtained within 15 min of the theoretical sampling time
-24 hr - <48 hr postdose may be obtained within 1 hr of the theoretical sampling time
-48 hr – ≤120 hr postdose may be obtained within 2 hr of the theoretical sampling time
- 1 20 – 168 hr postdose may be obtained within 6 hr of the theoretical sampling time
-> 168 hr postdose may be obtained within 24 hr of the theoretical sampling time
8.10.6 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase 1 assessment of ISLin humans, and the PK, pharmacodynamic, and safety 
profiles of the compound arestill being elucidated. This protocol is written with some 
flexibility to accommodate the inherent dynamic nature of Phase 1 clinical studies. 
Modificat ions to the dose, dosing regimen, and/or clinical or laboratory procedures currently 
outlined may be required to achieve the scientific goals of the study objectives and/or to 
ensure appropriate safety monitoring of the study participants.
As such, some al terations from the currently outlined dose and/or dosing regimen may be 
permitted based on newly available data, but the maximum daily dose may not exceed those 
currently outlined in the protocol.
•Decrease in the dose of the study intervention administered
•Modification of the PK sample processing and shippi[INVESTIGATOR_88647]
06CLSY
07ZLY5
PRODUCT: MK-8591  60
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
The PK/pharmacodynamic sampling scheme currently outlined in the protocol may be 
modified during the study based on newly available PK or pharmacodynamic data (eg , to 
obtain data closer to the time of peak plasma concentrations). If indicated, these collected 
samples may also be assayed in an exploratory manner for metabolites and/or additional 
pharmacodynamic markers.
Up to additional 50 mL of blood may be drawn f or safety, PK, and/or pharmacodynamic 
analyses. The total blood volume withdrawn from any single participant will not exceed the 
maximum allowable volume during his/her participation in the entire study (Appendix 8).
The timing of procedures for assessment of safety procedures (eg, vital signs, ECG, safety 
laboratory tests, etc.) may be modified during the study based on newly available data. 
Additional laboratory safety tests may be added to blood samples previously drawn to obtain 
additional safety inform ation. These changes will not increase the number of study 
procedures for a given participant during his/her participation in the entire study.
It is understood that the current study may employ some or none of the alterations described 
above. Any alterati on made to this protocol to meet the study objectives must be detailed by 
[CONTACT_21411] a letter to the Study File and forwarded to the investigator for retention. The 
letter may be forwarded to the IRB/IEC at the discretion of the investigator .
9 STATISTIC AL ANALYSIS PLAN
9.1 Statistical Analysis Plan Summary
This section contains a summary of the statistical analyses for this trial. Full detail is in the 
Statistical Methods (Section 9.6).
Pharmacokinetic s: Separately for each of the following PK parameter s,after a single dose 
administration of [ADDRESS_124809] for population ( participants with moderate hepatic
impairment, and healthy control participants ):individual values of plasma ISL AUC0 -∞, 
AUC0 -last, and Cmax ;PBMC ISL- TP AUC0 -∞, AUC0 -last, Cmax, C24, C168, and C672; 
andplasma M4 AUC0-∞ , AUC0 -last, and Cmax .  An unstructured covariance matrix will be 
used to allow for unequal population variances via the REPEATED and GROUP statement in 
SAS PROC MIXED.  Kenward and Roger's method will be used to calculate the 
denominator degrees of freedom for the fixed effect (DDFM=KR).  Ninety -five percent 
(95%) CIs for the least squares means for each population will be constructed on the natural 
log scale and will reference the t -distribution.  Exponentiating the least -squares means and 
their corresponding 95% CIs will yield estimates for the population geometric means and 
confidence intervals about the geometric means on the original scale.  
To address the primary estimation objective and compare participants with moderate hepatic 
impairment to participants with normal hepatic function, a two sided 90% confidence interval 
for the true difference in means ( moderate hepatic impairment –normal hepatic function) 
will be calculated for each PK parameter using the mean square err or from the model and 
06CLSY
07ZLY5
PRODUCT: MK-8591  61
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
referencing a t -distribution.  These confidence limits will be exponentiated to obtain the 90% 
confidence interval for the true ratio of geometric means ( moderate hepatic impairment/
normal hepatic function) for each PK parameter.
Safety:The safety and tolerability of ISLwill be monitored by [CONTACT_111962] (e.g., labs, vital signs, ECGs) .
Sample Size and Power Calculations: The between- subject standard deviations (on the 
natur al log scale) for plasma ISL AUC0- ∞ and Cmax, PBMC MK -8951- TP AUC0- ∞ and 
Cmax after administration of ISL observed in a previous study (PN003) are 0.[ADDRESS_124810](hr*nmol/L) , 0.356 ln(nmol/L) , 0.414 ln(hr* pmol/106Cells) and 0.518 ln(pmol/106Cells) , 
respectively. Assuming the same variability for 60- mg ISL, with 6 moderate hepatic
impairment participants and 6 healthy participants , the half width of the 90% confidence 
intervals of geometric mean ratios (GMR)s for plasma ISL AUC0 -∞ and Cmax, PBMC 
MK-8951- TP AUC0- ∞ and Cmax on the log scale will be 0.239, 0.372, 0.443, and 0.542 
respectively. The lower and upper 90% confidence limits for the true GMRs will be given by 
[CONTACT_111963]/1.27 and OBS*1.27 for plasma ISL AUC0 -∞, OBS/1.45, and OBS*1.45 for plasma ISL 
Cmax, OBS/1.54 and OBS*1.54 for AUC0 -∞ ISL- TP in PBMC, OBS/1.72, and OBS*1.[ADDRESS_124811] auspi[INVESTIGATOR_26338], the Early Clinical Development Statistics Department in collaboration 
with the Quantitative Pharmacology and Pharmacometrics Department and Translational 
Pharmacology Department of the Sponsor.
If, after the study has begun, changes are made to the statistical analysis plan stated below, 
then these deviations to the plan will be listed, along with an explanation as to why they 
occurred, in the Clinical Study Report.
9.3 Hypotheses/Estimation
Estimation: In partic ipants with moderate hepatic impairment, plasma pharmacokinetics 
(AUC0-∞ , Cmax) of ISLfollowing a single 60 mg ISLdose will be estimated and compared 
to those observed in healthy mean matched control participants .
9.4 Analysis Endpoints
Primary Endpoints
The primary PKendpoints include plasma ISLAUC0 -∞, AUC0 -last, Cmax, Tmax, apparent 
terminal t½, CL/F, and Vz/F. 
06CLSY
07ZLY5
PRODUCT: MK-8591  62
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Secondary Endpoints 
The secondary PK endpoints include AUC0- ∞, AUC0 -last, Cmax, C24, C168, C672, Tmax, 
and apparent terminal t ½ of ISL-TP in PBMC . The secondary safety endpoints include 
adverse experiences, laboratory safety tests, ECGs, and VSs. 
Exploratory Endpoints: 
The exploratory endpoints include AUC0 -∞, AUC0 -last, Cmax, and Tmax of M4 in plasma. 
The exploratory endpoints also include Ae, CLr, and feof ISL and M4 in urine. 
9.5 Analysis Populations
The following populations are defined for the analysis and reporting of data. All participant s 
willbe reported, and their data analyzed, according to the treatment(s) they actually received.
All participants as Treated (APaT): The All participants as Treated Population consists of all
participant s who received at least one dose of treatment. This population will be used for
assessments of safety and tolerability.
Per-Protocol (PP): The Per -Protocol Population consists of the subset of participant s who 
comply with the protocol sufficiently to ensure that generated data will be likely to exhibit 
the effects of treatment, according to the underlying scientific model. Compliance covers 
such considerations as exposure to treatment, availability of measurements and absence of 
important protocol deviations. Important protocol deviations will be identified to the extent 
possible prior to unblinding by [CONTACT_111964]/compliance, and its 
analysis and interpret ation. Any participant s or data val uesexcluded from analysis will be 
identified, along with their reason for exclusion, in the CSR. At the end of the study, all 
participant s who are compliant with the study pr ocedure as aforementioned and have 
available data considered sufficient to exhibit the effect of treatment will be included in the
Per-Protocol dataset. This population will be used for the PK analyses.
9.[ADDRESS_124812] for population ( participants with moderate hepatic impairment, and healthy 
control participants ):individual values of plasma ISL AUC0 -∞, AUC0 -last, and Cmax;
PBMC ISL- TP AUC0 -∞, AUC0 -last, Cmax, C24, C168, and C672; and plasma M4 AUC0-
∞, AUC0 -last, andCmax .  An unstructured covariance matrix will be used to allow for 
unequal population variances via the REPEATED and GROUP statement in SAS PROC 
MIXED.  Kenward and Roger's method will be used to calculate the denominator degrees of 
freedom for the fi xed effect (DDFM=KR).  Ninety -five percent (95%) CIs for the least 
squares means for each population will be constructed on the natural log scale and will 
reference the t- distribution.  Exponentiating the least -squares means and their corresponding 
06CLSY
07ZLY5
PRODUCT: MK-8591  63
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
95% CIs will yield estimates for the population geometric means and confidence intervals 
about the geometric means on the original scale.  Sample SAS code is given below:
proc mixed data=data;                                                                                                                   
   class population ;                                                                                                           
   model lnpk = population /ddfm=kr;                                                                                                    
   repeated/ group= population type=UN ;                                                                                 
   lsmeans population /cl alpha=0.05; 
   estimate ‘moderate/normal’ population 1 -1/cl alpha=0.1; 
run;    
To address the primary estimation objective and compare participants with moderate hepatic 
impairment to participants with normal hepatic function, a two -sided 90% confidence 
interval for the true difference in means ( moderate hepatic impairment –normal hepatic 
function) will be calculated for each PK parameter using the mean square error from the 
model and referencing a t -distribution.  These confidence limits will be exponentiated to 
obtain the 90% confidence interval for the true ratio of geometric means ( moderate hepatic 
impairment/normal hepatic function) for each PK parameter.
Figures showing individual PK values with GMs (95% CIs) by [CONTACT_66067], plotted o n the 
natural log scale, will be provided for plasma ISL AUC0 -∞, AUC0 -last,and Cmax ;PBMC 
ISL-TP AUC0 -∞, AUC0 -last, Cmax, C24, C168, and C672; and plasma M4 AUC0-∞ , 
AUC0 -last, and Cmax .
Individual values will be listed for each PK parameter including plasma ISL AUC0-∞ , 
AUC0 -last, Cmax, Tmax, apparent terminal t½, CL/F, and Vz/F, PBMC ISL- TP AUC0 -∞, 
AUC0 -last, Cmax, C24, C168, C672, Tmax, apparent terminal t½, plasma M4 AUC0-∞ , 
AUC0 -last, Cmax, Tmax , and Ae, CLr, and fe of ISL and M4 in urine by [CONTACT_66067], and the 
following (non -model -based) descriptive statistics will be provided: N (number of 
participants with non- missing data), arithmetic mean, standard deviation, arithmetic  percent 
CV (calculated as [ADDRESS_124813] deviation/arithmetic me an), median, minimum, maximum, 
geometric mean, and geometric percent CV (calculated as  100 x sqrt(exp(s2) -1), where s2is 
the observed variance on the natural log -scale).
The relationship between ISL pharmacokinetics and hepatic insufficiency will be e xamined 
in an exploratory manner via a scatter plot of PK values ( ISL plasma AUC0 -∞, AUC0 -last
and Cmax) versus the Child -Pugh score. Plots of PK values ( ISL plasma AUC0 -∞, AUC0 -
lastand Cmax) and the baseline laboratory components of the Child -Pugh score (i.e., 
bilirubin, albumin levels, and prothrombin time) will be provided.  Plots of PK parameter 
values ( ISL plasma AUC0 -∞, AUC0 -lastand Cmax ) vs age and body weight will also be 
provided . 
Safety: The safety and tolerability of ISLwill be monitored by [CONTACT_111962] (e.g., labs, vital signs, ECGs) .
06CLSY
07ZLY5
PRODUCT: MK-8591  64
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
9.7 Interim Analyses
Not applicable. 
9.8 Multiplicity
There is nopre-specified hypothesis ; therefore, no multiplicity adjustment is needed.
9.[ADDRESS_124814] deviations (on the natural log scale) for plasma ISL AUC0 -∞ 
and Cmax, PBMC MK -8951- TP AUC0- ∞ and Cmax after administration of ISL observed in 
aprevious study (PN003) are 0.228 ln(hr*nmol/L) , 0.356 ln(nmol/L) , 0.414 ln(hr* pmol/106
Cells) and 0.518 ln(pmol/106Cells) , respectively. Assuming the same variability for 60 -mg 
ISL, with 6 moderate hepatic impairment participants and 6 healthy participants, the half 
width of the 90% confidence intervals of geometric mean ratios (GMR)s for plasma ISL 
AUC0 -∞ and Cmax, PBMC MK -8951- TP AUC0- ∞ and Cmax on the log scale will be 0.239, 
0.372, 0.443, and 0.542 respectively. The lower and upper 90% confidence limits for the true 
GMRs will be given by [CONTACT_111963]/1.27 and OBS*1.27 for plasma ISL AUC0 -∞, OBS/1.45, and 
OBS*1.45 for plasma ISL Cmax, OBS/1.54 and OBS*1.54 for AUC0 -∞ ISL -TP in PBMC, 
OBS/1.72, and OBS*1.[ADDRESS_124815]: MK-8591  65
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_124816] for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Pro tection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data prote ction laws and
regulations), and International Council for Harmonisation Good Clinical Practice (ICH- GCP), and also in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific sta ndards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator- initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis-driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial and shall respect the data pr otection rights of all participants, trial site staff and, where 
applicable, third parties . Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess th e ability 
to successfully conduct the trial.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
06CLSY
07ZLY5
PRODUCT: MK-8591  66
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124817] operating procedures. Per MSD policies and procedures, if
potential fraud, scientific/research misconduct, privacy incidents/breaches orClinical Trial -related 
Significa nt Quality Issues are reported, such matters are investigated . When necessary, appropriate corrective 
and/or preventative actions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD s eeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing; in such cases, publication of result s may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the recommendations published by [CONTACT_111965] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and pr otocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form , investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eli minate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. 
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national re gulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from an MSD trial at any tim e, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible , as well as all 
applicable data protection rights . Unless required by [CONTACT_2371], only the investigator, Sponsor (or individuals acting on 
behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records 
that might identify the par ticipant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_88709].
06CLSY
07ZLY5
PRODUCT: MK-8591  67
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the investigator or sponsoring 
institution is being paid or provided a grant for perfor ming the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a s ource of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is requir ed. It is the investigator's/subinvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrang ements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly known as a fina ncial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.[ADDRESS_124818]: MK-8591  68
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related d ata will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by [CONTACT_111966] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnish ed to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulatio ns.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496] .
10.1.[ADDRESS_124819]: MK-8591  69
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124820] 
proprietary inform ation and to provide comments.
Authorship will be determined by [CONTACT_111967] .
10.1.5 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study is solely responsible for determining whether the study and its result s 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requi rements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_111968].
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive ,or other l ocally mandated registries are that of the 
Sponsor and agrees not to submit any information about this study or i ts results to those 
registries.
10.1.[ADDRESS_124821] the stud y in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, International C ouncil on Harmoni sation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally accepted 
standards of GCP ); and all applicable federal, state and local laws, rules and regulations 
relating to the conduct of the clinical study.
The Code of Conduct, a collection of goals and considerations th at govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
provi ders, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
06CLSY
07ZLY5
PRODUCT: MK-8591  70
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studies. The inves tigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entri es are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and audit at reasonable times by [CONTACT_111969] e Sponsor or any 
regulatory authorities. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_124822]: MK-8591  71
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or party without written notification to the Sponso r.
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that incl ude al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original ent ry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source document s or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available .
10.1.9 Study and Site Closure
The Sponsor or its desi gnee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s).
06CLSY
07ZLY5
PRODUCT: MK-8591  72
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed i n Table 6will be performed by [CONTACT_12082].
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol .
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Table 6 Protocol -require d Safety Laboratory Assessments
Laboratory 
Assessments Parameters
Hematology Platelet Count RBC Indices:
MCV
MCH
%ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Chemistry Blood Urea 
Nitrogen (BUN)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -
Oxaloacetic 
Transaminase 
(SGOT)Total bilirubin 
(and direct 
bilirubin, if total 
bilirubin is 
elevated above 
the upper limit 
of normal)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase 
(SGPT)Total Protein
Glucose 
(fasting)Calcium Alkaline 
phosphataseGamma 
glutamyl 
transpeptidase 
(GGT)
Coagulation•PT/INR (International normalized ratio, for hepatic impaired 
participants only)
Routine 
Urinalysis•Specific gravity
•pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, 
leukocyte esterase] by [CONTACT_5230]
•Microscopic examination (if blood or protein is abnormal)
06CLSY
07ZLY5
PRODUCT: MK-8591  73
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Laboratory 
Assessments Parameters
Other 
Screening 
TestsFollicle -stimulating hormone (as needed in women of nonchildbearing 
potential only)
Serum or urine alcohol and drug screen (to include at minimum: 
amphetamines, barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids and 
benzodiazepi[INVESTIGATOR_1651]).  Alcohol breath test for alc ohol screen is permitted.  
Serum or urine β human chorionic gonadotropin (β hCG) pregnancy test 
(as needed for WOCBP)
Serology (HIV- 1 and HIV -2antibodies in all participants, hepatitis B 
surface antigen [HBsAg], and hepatitis C virus antibody in healthy 
participants only
GC/CT (gonorrhea + chlamydia), Syphilis serologic, or Trichomonas 
testing may be done at screening per site SOP
HIV-[ADDRESS_124823] -
trial visit.
NOTES:
Laboratory safety tests will be p erformed after at least an 8- hour fast. Pre -dose Day 1 
laboratory procedures can be conducted up to 24 hours prior to study drug administration.
The i nvestigator (or medically qualified designee) must document their review of each 
laboratory safety report.
06CLSY
07ZLY5
PRODUCT: MK-8591  74
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
    An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
    
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
    NOTE: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine , diagnostic 
agent, medical device, combination product, or protocol specified procedure whether 
investigational or marketed (including placebo, active comparator product, or run -in 
intervention) , manufactured by, licensed by, provided by, or distributed by [CONTACT_88715].
Events meeting the AE definition
    Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
    Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.
    New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
    Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction .
    Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
    For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”
06CLSY
07ZLY5
PRODUCT: MK-8591  75
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
Events NOT meeting the AE d efiniti on
    Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
    Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
    Antici pated day- to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
    Surgery planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
    Refe r toSection 8.4.[ADDRESS_124824] medical occurrence that, at any dose:
a.   
Resu lts in death
b.   Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have cause d death, if it were more severe.
c.   Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not an SAE. )A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.   Results in persistent or significant disability/incapacity
•The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life fu nctions but do not constitute a substantial disruption.
06CLSY
07ZLY5
PRODUCT: MK-8591  76
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
e.   Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
f.   Other important medical events
•Medical or scientific judgment should be e xercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
    When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
    The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each exa mination.
·    It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
    There may be instances when copi[INVESTIGATOR_19360]. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
06CLSY
07ZLY5
PRODUCT: MK-8591  77
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
    The investigator will attempt to establish a diagn osis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of i ntensity /toxicity
    An event is defined as “serious ”when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable s afety event) by [CONTACT_111970], version 2.1. Any AE which 
changes DAIDS grade over the course of a given epi[INVESTIGATOR_19362]/worksheets.
-Grade 1 Mild event : Mild symptoms causing no or minimal interference with usual 
social and functional activities with intervention not indicated.
-Grade 2 Moderate event : Moderate symptoms causing greater than minimal 
interference w ith usual social and functional activities with intervention indicated.
-Grade 3 Severe event: Severe symptoms causing inability to perform usual social and 
functional activities with intervention or hospi[INVESTIGATOR_374].
-Grade 4 Potentially life -threa tening event: Potentially life -threatening symptoms 
causing inability to perform basic self -care funtions with intervention indicated to 
prevent permanent impairment, persistent disability, or death.
-Grade 5 Death: Deaths related to an AE.
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intende d as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Spon sor’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_4382] 
06CLSY
07ZLY5
PRODUCT: MK-8591  78
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
count, diary, etc.), expected pharmacologic effect, or measurement of 
drug/metabolite in bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal se quence from 
administration of the Sponsor ’s product? Is the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal 
product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor ’s product discontinued or dose/exposure/frequency 
reduced?
◦If yes, did the AE resolve or improve?
◦If yes, this is a positive dechallenge.
◦If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despi[INVESTIGATOR_55530] ’s 
product; (3) the study is a single -dose drug study; or (4) Sponsor ’s product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in this 
study?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦If no, this is a negative rechallen ge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose drug study; or (3) Sponsor ’s 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE TH AT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_93333], A ND IF REQUIRED, THE 
IRB/IEC .
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor ’s product or drug class 
pharmacology or toxicology?
06CLSY
07ZLY5
PRODUCT: MK-8591  79
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
•The assessment of relationship will be reported on the case report forms/worksheets by 
[CONTACT_19427] a qualified physician according to his/her best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility of Sponso r’s product relationship:
◦There is evidence of exposure to the Sponsor ’s product. The temporal sequence of 
the AE onset relative to the administration of the Sponsor ’s product is reasonable. 
The AE is more likely explained by [CONTACT_1034] ’s product than by [CONTACT_5748].
-No, there is not a re asonable possibility of Sponsor’ s product relationship:
◦Participant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not reasonable OR 
the AE is more likely explained by [CONTACT_26372]’s product. 
(Also entered for a participant wi th overdose without an associated AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
•There may be situations in which an SAE has occurred and the invest igator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•The i nvestigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.
•The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE and SAE
    The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
    New or updated information will be recorded in the CRF.
    The i nvestigator will submit any updated SAE data to the Sponsor within [ADDRESS_124825]: MK-8591  80
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
    The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
◦Reference Section 8.4.1 for reporting time requirements.
    The site will enter the SAE data into the electronic system as soon as it becomes 
available.
    After the study is c ompleted at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
    If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after t he EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
    Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via 
paper CRF
    If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
    In rare circumstances and in the absence of facsimile equi pment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
    Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames.
    Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
06CLSY
07ZLY5
PRODUCT: MK-8591  81
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.4 Appendix 4: Medical Device and Drug- device Combination Products : Product 
Quality Complaints/Malfunction s: Definition s, Recording, and Follow -up
Not applicable.
06CLSY
07ZLY5
PRODUCT: MK-8591  82
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile foll owing menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evalu ation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_124826]: MK-8591  83
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctly.
•Progestogen -only contraceptive implantc,d
•IUSc,e
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexua l partner of the WOCBP 
and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be 
used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia for a male participant can come from the site personnel’s review of the 
participant’s medical records, medical examination, or medical history interview.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consisten tly and correctly.
•Combined (estrogen -and progestogen -containing) hormonal contraceptionc,d
- Oral
- Intravaginal
- Transdermal
- Injectable
•Progestogen -only hormonal contraceptionc,d
- Oral
- Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
•Progesterone -only hormonal contraception where inhibition of ovulation is not t he primary mode of action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double barrier 
methods)f
a   Contraceptive use by [CONTACT_93335].
b   Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consist ently and correctly).
c   Male condoms must be used in addition to female participant hormonal contraception.
d   If locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to those which 
inhibit ovulation. 
e   IUS is a progestin releasing IUD.
f   A combination of male condom with either cap, diaphragm, or sponge with spermicide are considered acceptable, but not 
highly effective, birth control methods. 
Note: The following are not acceptable methods of contr aception:
-  Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and LAM.
-  Male and female condom should not be used together (due to risk of failure with friction).
06CLSY
07ZLY5
PRODUCT: MK-8591  84
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.  Definitions
a.   Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or diseas e. A biomarker may be 
used to see how well the body responds to a treatment for a disease or condition.1
b   Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.   Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d.   DNA: Deoxyribonucleic acid.
e.   RNA: Ribonucleic acid.
2.
  Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8. 9will be 
used in various experiments to understand:
◦The biology of how drugs/vaccines work
◦Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
◦Other pathways with which drugs/vac cines may interact
◦The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimen s will be used by [CONTACT_63558].
3.  Summary of Procedures for Future Biomedical Researc h
a.   Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in future 
biomedical research.
06CLSY
07ZLY5
PRODUCT: MK-8591  85
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
b.   In formed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study visit 
by [CONTACT_63559] d esignate. Informed consent for future biomedical 
research should be presented to the participants on the visit designated in the SoA. If 
delayed, present consent at next possible Participant Visit. Consent forms signed by [CONTACT_111971].
A template of each study site’s approved informed consent will be stored in the Sponsor’s 
clinical document repository.
c.   eCRF Documentation for Future Biomedical Research Specime ns
Documentat ion of participant consent for future biomedical r esearch will be captured in 
the eCRFs . Any specimens for which such an informed consent cannot be verified will be 
destroyed.
d.   Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined in 
the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical r esearch, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.  Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant s' clinical informat ion with future test results. In 
fact,little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and proce dures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
06CLSY
07ZLY5
PRODUCT: MK-8591  86
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124827] party (eg, a university investigator) designated by 
[CONTACT_1034]. Th e investigator conducting the analysis will follow the Sponsor’s privacy 
and confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope o f analysis outlined in future biomedical research protocol and consent. 
Futur e biomedical r esearch specimens remaining with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.  Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical r esearch and a sk that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at any time by [CONTACT_111954]. If medical records 
for the main study are still available, the investigator will contact [CONTACT_111972] ([EMAIL_1250]). Subsequently, the 
participant's specimens will be flagged in the biorepository and restricted to main study 
use only. If specimens were collected from study participants sp ecifically for future 
biomedical r esearch, these specimens will be removed from the biorepository and 
destroyed. Documentation will be sent to the investigator confirming withdrawal and/or 
destruction, if applicable. It is the responsibility of the investigator to inform the 
participant of completion of the withdrawal and/or destruction, if applicable. Any 
analyses in progress at the time of request for withdrawal/destruction or already 
performed prior to the request being received by [CONTACT_111973]. No new analyses would be generated 
after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_111974]) or the specimens have been completely anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for wit hdrawal of consent and/or destruction cannot be processed.
7.  Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository for potential 
analysis for up to [ADDRESS_124828]: MK-8591  87
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124829] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly s ecure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.  Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability, and conc erns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_111939] a nd participants. Participants will not be 
identified by [CONTACT_88726].
10. Future Biomedical Research Study Population
Every effort will be made to recruit all particip ants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biom edical r esearch informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In t his highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly to 
[EMAIL_1250].
06CLSY
07ZLY5
PRODUCT: MK-8591  88
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
13.References
1.  National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.  International Council on Harmoni sation [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomic s, Pharmacogenetics, Genomic Data and Sample Coding 
Categories. Available from http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -
genomic -data-and-sample -cod.html 
3.  Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope 
and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/ 
4.  Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
06CLSY
07ZLY5
PRODUCT: MK-8591  89
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.7 Appendix 7: Country -specific Requirements
Not applicable
06CLSY
07ZLY5
PRODUCT: MK-8591  90
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.8 Appendix 8:Blood Volume Table
All Participants Pre-studyTreatment 
PeriodPost-
studyTotal 
CollectionsmL Per 
CollectionTotal 
mL/ Test
Laboratory Safety Tests ( all 
participants ; includes FSH if 
applicable, β- hCG if applicable, 
and HIV/Hepatitis screen)2 2 1 5 17 85b
Blood for Genetic Analysis 0 1 0 1 8.5 8.5
Blood for PBMC ISL -TP 0 11 0 11 16 176
Blood for Plasma ISL 0 16 0 16 4 64
Blood for plasma M4 0 16 0 16 3 48
Total Blood Volume per Participant a381.5 mL
a.If additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood (up to 50mL) 
may be obtained. Note: never to exceed 50 mL.
bTotal blood volume for laboratory safety tests (including screening tests) throughout the stu dy but may be a lower
volume based on site’s SOP .  Additionally, HIV- [ADDRESS_124830]: MK-8591  91
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.9 Appendix 9: 12-Lead Electrocardiogram Abnormality Criteria
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure CriteriaPotentially Significant 
Postrandomization Findings 
(clarification on action to take)
RHYTHM
Sinus Tachycardia 110 bpmHR >110 bpm and HR increase 
of ≥25bpm from baseline
Sinus Bradycardia <40 bpmHR <40 bpm and HR decrease of 
≥5bpm from baseline
Sinus Pause/Arrest >2.0 seconds >2.0 seconds
Atrial Premature Complex 1 beat 3 beats
Ventricular Premature 
ComplexAll 3 beats
Ectopic Atrial Rhythm None None
Junctional RhythmJunctional Rhythm with HR 
<40 bpmJunctional Rhythm with HR <40 
bpm
Idioventricular Rhythm All All
Atrial Fibrillation All All
Atrial Flutter All All
Supraventricular Tachycardia All All
Ventricular Tachycardia All All
AXIS
Left Axis DeviationRBBB With Left Anterior 
Hemiblock (LAHB)New Onset LAHB
Right Axis DeviationRBBB With Left Posterior 
Hemiblock (LPHB)New Onset LPHB
CONDUCTION
1st Degree AV Block PR 230 msPR 230 ms  + Increase of  15 
ms; or PR Increase of >25%
2nd Degree AV Block Mobitz Type II Mobitz Type II
3rd Degree AV Block All All
LBBB All All
RBBBRBBB With LAHB/LPHB as 
Defined AboveNew Onset RBBB (Not 
Including Rate -related)
Incomplete Right BBB 
(ICRBBB) (QRS <120 ms)No Exclusion Nothing
Short PR/ Preexcitation 
SyndromeDelta Wave + PR <[ADDRESS_124831] + PR <[ADDRESS_124832]: MK-8591  92
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure CriteriaPotentially Significant 
Postrandomization Findings 
(clarification on action to take)
Other Intra -Ventricular 
Conduction DelayQRS 130 msQRS 130 ms + Increase of 10 
ms
QTc (B or F)
Male QTc 470 msQTc 500 ms or Increase of 60 
ms From Baseline
Female QTc 480 msQTc 500 ms or Increase of [ADDRESS_124833]/T MORPHOLOGY
ST Elevation Suggestive of 
Myocardial Injury In [ADDRESS_124834] -T Changes 
(In 2 or More Leads)No exclusion In 2 or more contiguous leads
PACEMAKER All All
Baseline is defined as Predose Day 1; ms=milliseconds, mm=millimeter
06CLSY
07ZLY5
PRODUCT: MK-8591  93
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory values obtained at prestudy (screening) visit and/or predose evaluation:
A.If all protocol- specified laboratory values are normal, the participant may enter the study.
B.If a protocol specified laboratory value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study.
C.If ≥1 protocol -specified laboratory value not specified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
1.The participant may be excluded from the study;
2.The participant may be included in the study if the abnormal value(s) is NCS (the 
investigator must annotate the laboratory value “NCS” on the laboratory safety test 
source d ocument).
3.The participant may be included in the study if the abnormality is consistent with a 
pre-existing medical condition which is not excluded per protocol (eg, elevated 
eosinophil count in a participant with asthma or seasonal allergies), the medical
condition should be annotated on the laboratory report .
OR
4.The abnormal test may be repeated (refer items a. and b. below for continuation of 
algorithm for repeated values).
a.   If the repeat test value is within the normal range, the participant may ent er the 
study.
b.   If the repeat test value is still abnormal, the study investigator will evaluate the 
potential participant with a complete history and physical examination, looking 
especially for diseases that could result in the abnormal laboratory value in 
question. If such diseases can be ruled out, and if the abnormal laboratory value is 
not clinically relevant, then the participant may enter the study.
D.If there is any clinical uncertainty regarding the significance of an abnormal value, the 
participant will be excluded from the study.
06CLSY
07ZLY5
PRODUCT: MK-8591  94
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
10.11 Appendix 11: Abbreviations
Abbreviation Expanded Term
3TC Lamivudine
ADA adenosine deaminase
Ae Amount excreted in urine
AE adverse event 
AIDS Acquired immunodeficiency syndrome
ALT Alanine aminotransferase
AN Allocation number
APaT All participants as Treated
AR adverse reaction
ART Anti-retroviral therapy
ARV Antiretroviral
AST Aspartate aminotransferase
ATP adenosine triphosphate
AUC Area under the concentration -time curve
AUC0 -[ADDRESS_124835] dose
Cmax Maximum concentration
CI confidence interval
CLr Renal clearance
CL/F Apparent clearance after extravascular administration
CRF Case Report Form 
CRU clinical research unit
CV coefficient of variation
DAIDS Division of AIDS
DDI Drug -drug interaction
DILI drug-induced liver injury
DOR Doravirine 
DP Diphosphate 
DTG Dolutegravir 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
06CLSY
07ZLY5
PRODUCT: MK-8591  95
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124836]
eCRF electronic Case Report Form
eCTA exploratory Clinical Trial Application
EDC electronic data collection 
EMA European Medicines Agency
FBR Future biomedical research
FDA Food and Drug Administration 
FDC Fixed dose combination
fe fraction of dose excreted in urine
FSH follicle stimulating hormone 
GC/CT Gonorrhea/chlamydia
GCP Good Clinical Practice 
GCV geometric coefficient of variation
GGT Gamma glutamyl transpeptidase
GLP good laboratory practice
GM geometric mean
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HCV Hepatitis C virus 
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therapy
IB Investigator’s Brochure 
IC50 50% inhibitory concentration 
ICC intraclass correlation
ICF Informed Consent Form
ICH International Council on Harmonization
IEC Independent Ethics Committee
I/E Inclusion/Exclusion
IMP investigational medicinal product
IND Investigational New Drug 
INR International normalized ratio 
IRB Institutional Review Board
LNG/EE Levonorgestrel/ethinyl estradiol
ISL Islatravir
ISL-DP Islatravir -diphosphate
ISL-TP Islatravir -triphosphate
MedDRA Medical Dictionary for Regulatory Activities
M4 metabolite M4
MCV Mean corpuscular volume
MCH Mean corpuscular hemoglobin
06CLSY
07ZLY5
PRODUCT: MK-8591  96
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_124837] operating procedure 
STI sexually transmitted infection
t1/2 Half-life
TDF Tenofovir disoproxil fumarate
TK toxicokinetic
Tmax time of maximum concentration
TP Triphosphate
UDS urine drug screen
VS vital sign
Vz/F Apparent volume of distribution during the terminal phase
WBC white blood cell 
WOCBP woman/women of childbearing potential 
WONCBP woman/women of non- childbearing potential
06CLSY
07ZLY5
PRODUCT: MK-8591  97
PROTOCOL/AMENDMENT NO.: 030-01 
MK-8591 -030-01FINAL PROTOCOL 29-APR -2021
11 REFERENCES
Not applicable.
06CLSY
07ZLY5